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Abbreviations
CABG Coronary Artery Bypass Surgery
DES Drug Eluting Stent
EPC Endothelial Progenitor Cell
IABP Intra Aortic Balloon Pumping
IRV Infarct Related Vessel
LVEF Left Ventricular Ejection Fraction
MACE Major Adverse Cardiac Events
MOHRI Ministry of Health Republic Indonesia
PCI Percutaneous Coronary Intervention
PES Paclitaxel-eluting Stent
QCA Quantitative Coronary Angiography
RES Rapamycin-eluting stent
STEMI ST Elevation Myocardial Infarction
TIMI Thrombolysis in Myocardial Infarction
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Chapter 1 
Introduction and outline
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Indonesia is the largest archipelago in the world, with an estimated total of 17,504 
islands, of which only about 6,000 are inhabited. The five main islands are Sumatra, 
Java/Madura, Kalimantan, Sulawesi and Papua. Indonesia consists of more than 300 
ethnic groups, hundreds of native languages and several religions spreading out 
throughout the islands. All people are united in one country, one nation and one 
language, Indonesia. It is not surprising that the national motto is “Bhinneka Tunggal 
Ika” , meaning “Unity in Diversity” . Administratively, Indonesia has been divided into 
33 provinces (figure 1).
Figure 1
REPUBLIC OF INDONESIA
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The total population of Indonesia is about 220 million. Data on medical statistics are 
collected by several institutions, including the division of Medical Care of the Ministry 
of Health Republic Indonesia (MOHRI) and the Badan Pusat Statistik (BPS-Statistics 
Indonesia), a Non-Departmental Government Institution directly responsible to the 
president, collecting general statistics, including demographics, at both the national
. -  s 'it
Provinces
1 Nanggroe Aceh Darussalam
2 North Sum atera
3 W est Sum atera
4 Rlau
5 Jamb I
6 South Sumatera
8 Lampung 15 E sst Java 22 South Kalimantan
9 Bangka Belitung 16 Banten 23 East Kalimantan
10 Riau Islands 17 Bali 24 North Sulawesi
11 DKI Jakarta 18 W est Nusa Tenggara 25 Central Sulawes
12 W est Java 19 E sst Nusa Tenggara 26 South Sulawesi
13 Central Java 20 W est Kalim antan 27 Southeast Sulawesi
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and provincial level. Also the World Health Organization (WHO) collects data since 
Indonesia joined this organization in 1950. The Indonesian health care providers 
represent a mix of public and private institutions, with in 2007 approximately 1300 
general hospitals, roughly half of them owned by private investors, Source: DG of 
Medical Care Ministry o f Health Republic Indonesia (MOHRI). Although there is an 
increasing number of insurance-based financial schemes in the health sector, the 
majority of Indonesians are still paying out-of pocket for their health care.
The burden of cardiovascular disease
As in many Western countries, atherosclerosis, particularly of the coronary arteries, is 
a major cause of morbidity and mortality in Indonesia nowadays. However, although 
substantial progress has been made in the understanding of the pathophysiology of 
atherosclerosis and treatment has significantly improved over the last decades, in 
2002 ischaemic heart disease was still the most common cause of death in Indonesia 
(14% of all causes) and accounted for an average of 8 life years lost (Source: Death 
and DALY estimates by cause, 2002;
http://www.who.int/entity/healthinfo/statistics/bodgbddeathdalyestimates.xls). The 
age-standardized mortality rate by ischaemic heart disease in Indonesia and several 
other countries are depicted in figure 2, showing the high death rate in Indonesia.
Figure 2
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There are several explanations for the high mortality rate due to ischaemic heart 
disease in Indonesia. First, the prevalence of smoking, diabetes and hypertension is 
high in Indonesia. Second, many patients with either diabetes or hypertension have 
sub-optimal treatment. Third, treatment options for several clinical presentations of 
ischaemic heart disease are not available everywhere in Indonesia. This may be 
caused both by limitations of the health care system, lack of awareness of patients 
and doctors, including recognition of symptoms, and lack of financial resources.
Although primary prevention of coronary artery disease is of key importance, we have 
to deal with the fact that in the next decades an increasing number of patients with 
clinical manifestations will be presented. The broad goals of treatment for patients 
with coronary artery disease are improvement in survival and a reduction in the risk 
of myocardial infarction and symptoms of coronary disease.
One of the most important and dangerous complications of coronary atherosclerosis 
is ST-elevation Myocardial Infarction (STEMI). In the majority of cases, it is caused 
by a ruptured atherosclerotic plaque resulting in subsequent acute closure of one of 
the large epicardial vessels, and if untreated, mortality is very high. The most 
important goal in the treatment of patients with STEMI is to achieve rapid, complete 
and sustained reperfusion of the infarct related vessel and the myocardial tissue it 
supplies. Compared to medical treatment by fibrinolysis, percutaneous coronary 
intervention (PCI) in patients with STEMI (“primary PCI”) is more effective in re­
opening the occluded vessel and is associated with reduced infarct size and a lower 
incidence of death and re-infarction. For these reasons, primary PCI has become the 
preferred therapy of patients with STEMI, provided the procedure is performed in a 
timely manner by experienced operators.
Although primary balloon angioplasty is very effective in restoration of coronary blood 
flow, there are still several limitations. Recurrent ischemia occurs in 10 to 15% after 
initially successful PCI, and silent or clinically apparent reocclusion of the infarct 
related vessel (IRV) occurs in 5 to 10%, whereas angiographic restenosis is 
observed in 30 to 50%. As a result, the need for subsequent target vessel 
revascularization (TVR) in the first 6 months remains disappointingly high. Although 
stenting has been shown to be superior to balloon angioplasty in reducing restenosis
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and the need for TVR, there is also a risk of acute closure of the stent (sub-acute 
stent occlusion), which is associated with high mortality.
Furthermore, although the beneficial effects of primary PCI for STEMI has been 
demonstrated in a number of trials, most studies were conducted in the western 
countries. Experience, logistics and patient characteristics may differ in other parts of 
the world, and the effects of primary PCI should also be evaluated in these countries.
This thesis
Primary PCI has been introduced after randomised controlled trials demonstrated its 
superiority over other reperfusion modalities in thebeginning of the nineties of the last 
century. Since then a number of studies have been performed, increasing our 
insights about important subjects as concomitant medication, thrombosuction and 
treatment after primary PCI.
The main objective of the studies presented in this thesis is to investigate the most 
optimal strategy for performing primary PCI. The studies were performed in close 
collaboration between Klinik Kardiovaskular, Hospital Cinere, Jakarta and the 
department of cardiology, Isala Klinieken, Zwolle, the Netherlands.
Main issues addressed in this thesis are:
1. Does the use of stents during primary PCI improves survival?
2. Are there differences in outcome between different drug eluting stents, used 
during primary PCI?
3. Are endothelial progenitor cells capturing stents safe during primary PCI in 
patients with STEMI?
4. Can primary PCI be performed safely, with good outcome in a starting 
heartcenter in Jakarta, Indonesia?
5. Are there major differences between primary PCI performed in Europe, as 
compared to Indonesia?
In the second chapter a brief review on current treatment of STEMI is given. After 
immediate reperfusion therapy, secondary prevention is very import to decrease 
death and risk of recurrent myocardial infarction. In chapter 3, use of the IIb/IIIa 
inhibitor tirofiban in myocardial infarction is discussed in more detail.
14
In the fourth chapter, balloon angioplasty is compared to coronary stenting. Although 
a number of randomised controlled trials has shown that stenting during primary PCI 
may decrease target vessel revascularization and recurrent myocardial infarction, 
there was no clear decrease of mortality after stenting. Moreover, the randomised 
trials excluded many patients, and many had a limited sample size. Furthermore, 
interpretation of results is difficult because of many cross-overs. To assess the 
potential association between mortality and stenting in patients undergoing primary 
PCI, analyses of a prospective registry was performed, with particular focus on 
mortality differences between patients with and without stenting.
Although a clinical benefit of drug eluting stents, as compared to bare metal stents, 
has been shown in several trials, it is still not clear which drug eluting stent has the 
most benefit. In chapter 5 and 6, a randomised controlled clinical trial and a meta­
analysis of two different coated stents for use in patients with STEMI are compared.
Stents have clear benefits in reducing the risk of restenosis and can immediately 
treat dissection(s) during and after (balloon) PCI. However, they have also limitations, 
such as acute or late stent thrombosis. In chapter 7 a concept of a new stent, coated 
with endothelial progenitor cells, is presented. Previously, the use of this stent for the 
treatment of STEMI was only reported in very small studies. We did an analysis of a 
large data-base of patients treated with primary PCI using this new stent.
Chapter 8 gives some data about the first experience with primary PCI in a starting 
Indonesian heart center (Klinik Kardiovaskular, Hospital Cinere). In particular 
attention is paid to short-term outcome and success of reperfusion. A very important 
chapter is the comparison of primary PCI between Indonesia and The Netherlands, 
and these results are presented in chapter 9. Not only potential differences in 
performing PCI, but also potential differences in baseline characteristics and logistics 
were studied.
In chapter 10 the studies are summarized and some conclusions are made. 
Furthermore, some future directions are explored.
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CHAPTER 2
Modern treatment of ST-elevation myocardial 
infarction (STEMI): a review
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Summary
Among the clinical presentations of coronary artery disease, ST segment elevation 
myocardial infarction (STEMI) has a high mortality and morbidity with increased risk 
of heart failure and cardiac arrhythmias, if treated not adequate. However, if treated 
well, most patients with STEMI have a very good prognosis. Timely and sustained 
restoration of infarct vessel patency is the major goal of initial treatment. If primary 
PCI is performed, (drug-eluting) stents may reduce restenosis, but effects on 
mortality are less obvious. Concomitant administration of aspirin, heparin, clopidogrel 
and glycoprotein IIb/IIIa antagonists should be considered, whereas possibly in the 
future bivalirudin may replace heparin and glycoprotein IIb/IIIa antagonists. 
Beta-adrenergic blockers, angiotensin-converting-enzyme inhibitors and statins 
should be initiated in all patients with STEMI and may reduce mortality and risk of 
heart failure or recurrent infarction. There is also some evidence about beneficial 
effects of aldosterone antagonists in patients with signs of heart failure. Patients with 
multi vessel coronary artery disease should receive revascularisation if ischemia is 
documented by non-invasive imaging. High-risk patients, particularly those with low 
ejection fraction, should receive an Implantable Cardioverter Defibrillator after 30 
days, although it is not clear whether patients after primary PCI also have benefits.
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Introduction
Although during the past decades knowledge increased and therapeutic possibilities 
improved, the prevalence of coronary artery disease is still high. The clinical 
presentations of coronary artery disease include stable angina, heart failure, 
arrhythmias and the acute coronary syndrome (ACS).
Of the patients with an ACS, particularly those with ST elevation myocardial infarction 
(STEMI) should be treated fast and aggressive, because if they are not treated or 
treated insufficiently, they may have a very bad prognosis. Treatment has been 
changed during the last decades, and prognosis has improved subsequently during 
this time period (figure 1). We review in this chapter the current treatment of STEMI.
Figure 1 - Hospital mortality in patients admitted for myocardial infarction in Zwolle in 
different time periods.
Hospital mortality (%)
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Diagnosis
All patients with suspected myocardial infarction should have rapid ECG recording 
and interpretation. There is a strong association between time delay and mortality in 
patients with STEMI treated by primary PCI (1). Also, the choice for reperfusion 
therapy is dependent on the durations of symptoms (2). All steps should be 
considered for improvement, including the patient’s ability to recognize their 
symptoms and to promptly contact the medical system, the time necessary to
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transport the patient to the hospital, the decision process on arrival, and the requisite 
time to implement the reperfusion strategy. If a diagnosis of STEMI is made, 
treatment with aspirin, heparin and (less clear) clopidogrel, beta blockers and GP IIa 
IIIb inhibitors should be initiated, and the patient should be transferred to a hospital, 
preferably a PCI center.
Reperfusion therapy
Reperfusion therapy (either mechanical or pharmacologic) is indicated for patients 
with chest pain with a duration of 12 hours or less in association with ST-segment 
elevation greater than 0.1 mV in two or more contiguous electrocardiographic leads 
or a new (or presumed new) left bundle-branch block.
Fibrinolytic therapy
In comparison with conservative management (medical treatment without reperfusion 
therapy), fibrinolytic therapy improves left ventricular systolic function and survival in 
patients with myocardial infarction associated with either ST-segment elevation or left 
bundle-branch block. Nowadays, fibrinolytic therapy can be considered in patients 
whose first medical contact occurs less than 1 hour after the onset of symptoms (in 
whom the therapy may abort the infarction) (3) and those with a history of 
anaphylaxis due to radiographic contrast material. However, primary PCI should be 
the first choice in the majority of patients. When primary PCI is not readily available, 
efficient prehospital treatment with (t-PA-based) fibrinolytic agents may reduce 
mortality when administered promptly (4). Rescue PCI should be considered for 
patients in whom reperfusion fails to occur after fibrinolytic therapy (5, 6). Small 
studies suggested beneficial effects of GP IIb/IIIa inhibitors in patients undergoing 
rescue PCI after failed thrombolysis, without a significant increase in bleeding or 
vascular complications (7, 8). Facilitated primary PCI is defined as the administration 
of fibrinolytic therapy to minimize myocardial ischemia time while waiting for PCI. 
Several studies have also assessed the combination of GP IIb/IIIa inhibitors with 
thrombolysis, using either standard doses of thrombolytic agents (TAMI 8, IMPACT- 
AMI, GUSTO V and PARADIGM) or reduced dosages of thrombolytic agents (TIMI
14, FINESSE and SPEED) for combination therapy. However, benefits were not clear 
and there was an increased risk of bleeding, suggesting that facilitated PCI cannot be 
recommended outside of experimental protocols at this time (9).
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Primary PCI
Primary PCI has a number of benefits over fibrinolysis. First, it can be offered to 
patients with contraindications for fibrinolysis. But more important, primary PCI 
restores angiographically normal flow, including optimal (TIMI) flow and blush, in the 
previously occluded artery in more than 90% of patients (10-12), whereas fibrinolytic 
therapy does so in only 50 to 60% of such patients.
Primary PCI causes also less frequently (intracranial) bleeding. Furthermore, about a 
quarter of patients receiving fibrinolytic therapy has reocclusion of the infarct-related 
artery within 3 months after the myocardial infarction, with a recurrent infarction (13). 
Therefore, primary PCI may be preferable, even if the "door-to-balloon" interval 
exceeds 90 minutes in patients with a contraindication to fibrinolytic therapy (14) a 
high risk of bleeding with fibrinolytic therapy (15), with clinical findings as tachycardia, 
hypotension, or pulmonary congestion suggesting a high risk of an infarct-related 
complicated medical course or death (16), and those with cardiogenic shock (17). 
There is a continuing controversy about the acceptable time-window for primary PCI. 
Recent American and European guidelines recommend primary PCI if the delay in 
performing PCI instead of administering fibrinolysis (PCI-related delay) is <60 min 
and the presentation delay is more than 3 hours.
Where primary PCI leads to an improved left ventricular systolic function, less 
complications (ie. stroke) and higher survival, the benefits of stenting are almost 
entirely due to a significantly lower need for repeat ischemia-driven revascularization. 
Among other studies, the CADILLAC study showed that the composite end points 
(death, reinfarction, disabling stroke, or ischemia-driven revascularization of the 
target vessel) were significantly lower with stenting compared to balloon angioplasty 
in patients with STEMI (18). As a result, stenting of the infarct-related artery may be 
preferred. As compared with bare-metal stents, drug-eluting stents may further 
reduce restenosis within 12 months after primary PCI (19-21). Among the drug- 
eluting stents, several studies have compared Sirolimus (SES) and paclitaxel (PES) 
eluting stents in patients with STEMI. In general, it seems to be that RES, compared 
to PES, significantly reduces the risk of reintervention and stent thrombosis with a 
trend toward a lower risk of MI without affecting mortality (22). In addition, another 
'olimus (everolimus) eluting stent has been shown to be superior to PES (23).
If drug-eluting stents are used in this setting, dual antiplatelet therapy (aspirin and 
clopidogrel) should be given for at least 12 months to decrease the incidence of
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subacute stent thrombosis. A number of studies have investigated potential benefits 
of GP IIb/IIIa inhibitors in patients with primary PCI for STEMI, including a significant 
reduction of the combined endpoint of death and recurrent myocardial infarction (24, 
25). An alternative for heparin is bivalirudin, a direct thrombin inhibitor (26). The 
Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial 
Infarction (HORIZONS-AMI) trial demonstrated a significantly lower mortality and 
bleeding event rate after on year in favor of bivalirudin monotherapy (with provisional 
GP IIb/IIIa receptor blockade) in comparison with unfractionated heparin plus GP 
IIb/IIIa blockade in patients undergoing primary PCI for STEMI (27), However, 
bivalirudin monotherapy was associated with a highly significant greater incidence of 
acute stent thrombosis. More randomized trials should confirm these observations, 
and also potential benefits of bivalirudin given in the ambulance. Distal embolization 
after primary PCI is related to more extensive myocardial damage and a poor 
prognosis (28, 29). Risk factors of distal embolization include infarct location, 
thrombus composition and size and diabetes (30). Thrombus aspiration before 
primary PCI may lead to better myocardial reperfusion and has been associated with 
lower enzyme release, and a lower risk of distal embolization and no-reflow (31).The 
Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial 
infarction Study (TAPAS) demonstrated even a reduction in cardiac death and the 
combination of cardiac death an recurrent myocardial infarction after one year (32).
Coronary artery bypass graft surgery
Coronary artery bypass graft surgery (CABG) is infrequently performed in patients 
with STEMI, but may be life saving in patients with failed primary PCI, particularly in 
patients with a large size of myocardium at risk. Also patients with left main or three- 
vessel disease but with restoration of blood flow either spontaneous or after balloon 
PCI may benefit of short-term CABG. Despite the higher surgical mortality rate after 
urgent CABG, a favorable long-term clinical outcome can be expected if the patients 
survive (33).
Intensive cardiac care
Several patients with STEMI are critically ill during the acute phase, with a very high 
risk of death. These patients include those after cardiac arrest, those with sustained 
ventricular arrhythmias and those with (progressive) heart failure.
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Mortality remains high in STEMI patients presenting with heart failure and particularly 
cardiogenic shock (34). Mechanical complications of myocardial infarction, as 
ventricular septal or mitral chorda rupture should be excluded or when diagnosed 
treated. Heart failure should be aggressive treated by inotropic drugs and avoiding 
negative intotropic drugs. Respiratory failure can be treated by (mechanical) 
ventilation (35). In patients with acute kidney injury following cardiogenic shock, renal 
replacement therapy should be considered (36). Intra-aortic balloon counterpulsation 
(IABP) in patients with cardiogenic shock is strongly recommended (class IB) in the 
current guidelines. However, a recent systematic review and meta-analysis showed 
that there is insufficient evidence endorsing the current guideline recommendation for 
the use of IABP therapy in the setting of STEMI complicated by cardiogenic shock 
(37). Also a recently published trial failed to show benefits of IABP in patients with 
cardiogenic shock complicating myocardial infarction (38). If available, left ventricular 
assist devices may improve prognosis in patients with severe heart failure (39), 
although also then prognosis remains poor.
A special type of heart failure is right ventricular dysfunction. It has been shown that 
RV dysfunction as assessed by echocardiography is an independent predictor for 
long-term mortality (40). Right ventricle heart failure should be treated by extra fluid 
and if necessary inotropics. It has been suggested that levosimendan is more 
effective than dobutamine for right ventricle dysfunction (41), but this should be 
confirmed by additional trials.
In patients with STEMI and cardiac arrest, conventional cooling methods to induce 
mild therapeutic hypothermia seem to improve survival and neurologic outcome after 
cardiac arrest (42, 43).
Sustained VT/VF remains a significant complication associated with an increased risk 
of in-hospital mortality (44). Early mortality is reduced after successful percutaneous 
coronary intervention, but remains elevated in this high-risk group (45).
Medication after reperfusion therapy
Beta-adrenergic blockers (46, 47) and angiotensin-converting-enzyme inhibitors (48) 
should be initiated in all patients, provided that the patient has no contraindications 
and is stable hemodynamically. Beta-blockers have indisputably been demonstrated 
to be clinically useful in the setting of acute Myocardial Infarction (MI) (49). Especially 
early metroprolol administration during acute coronary occlusion increases
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myocardial salvage (50). A meta-analysis of randomised trials could not demonstrate 
a short-term survival benefit of treatment with beta-blockers, but this was probably 
because of a negative effect in patients with heart failure (51 ). Patients with 
obstructive lung disease may receive less often beta blockers (52). However, 
although these patients should be treated with caution, the majority of these patients 
can safe use beta blockers (53).
In addition to aspirin, all patients should be treated with clopidogrel for 12 months 
(54), although in the future prasugrel may be an alternative, since it has been shown 
that prasugrel is more effective than clopidogrel for prevention of ischaemic events, 
without an apparent excess in bleeding in patients with STEMI (55).
Chronic therapy with an ACE inhibitor (unless contraindicated) for all patients after an 
STEMI is recommend. Angiotensin II receptor blocker (ARB) may be an alternative 
for patients unable to tolerate an ACE inhibitor, usually due to cough. ACE 
inhibitors/ARBs are most important in patients with heart failure, an LVEF less than 
40 percent, diabetes, or hypertension. The optimal approach is less clear in 
asymptomatic, normotensive, nondiabetic patients with no or minimal impairment in 
left ventricular function. Statin therapy at discharge is associated with a significant 
reduction in 1-year mortality after primary angioplasty for STEMI and is 
recommended for all patients with acute myocardial infarction (56, 57). Patients with 
signs of heart failure may benefit of aldosterone antagonists (58).
Rehabilitation
Although most studies are before the primary PCI erea, a trend is suggested towards 
decreased mortality with early mobilisaton after infarction (59). The identification of 
major modifiable risk factors for coronary heart disease (dyslipidemia, hypertension, 
smoking, obesity, inactivity, and diabetes) is a prerequisite to the implementation of 
rehabilitation and preventative interventions. Risk factor modification by therapeutic 
lifestyle changes, as well as drug therapies can decrease morbidity and mortality in 
such patients. Home and centre based forms of cardiac rehabilitation seem to be 
equally effective in improving clinical and health related quality of life outcomes in 
patients with a low risk of further events after myocardial infarction or 
revascularisation (60). Psychological interventions may reduce total cholesterol and 
standardized mean anxiety scores, interventions with behavioral components may be 
effective in reducing all-cause mortality and nonfatal myocardial infarction, and
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interventions with behavioral and/or cognitive components have been associated with 
reduced standardized mean depression scores (61).
Also exercise-based cardiac rehabilitation may be effective in reducing cardiac 
deaths, although it is less clear whether exercise only or a comprehensive cardiac 
rehabilitation intervention is more beneficial (62).
Additional revascularisation
After either primary PCI or fibrinolysis, (additional) revascularisation should be 
considered if ischemia is documented by non-invasive imaging. The ACC/AHA 
guidelines recommend exercise stress with imaging using radionuclide myocardial 
perfusion imaging (MPI) or echocardiography for patients who are able to exercise 
and vasodilator (adenosine or dipyridamole) MPI or dobutamine echocardiography 
for patients who cannot. Routine PCI of an occluded infarct artery three to 28 days 
after myocardial infarction will probably not reduce the occurrence of the death, re­
MI, and New York Heart Association class IV heart failure in comparison with patients 
assigned to optimal medical therapy alone (63).
Re-stenosis rates of the infarct related vessel are considerably higher in more 
complex lesion subsets, such as small vessels, long lesions, and bifurcations, and 
these patients should be monitored intensively, to detect myocardial ischemia. 
Patients with multivessel disease, have often an unfavorable clinical outcome, with 
also less improvement of LV function after the infarction. Additional revascularisation 
may be of benefit in these patients, with probably no mortality difference between 
patients treated by PCI or CABG during long-term follow-up (64, 65).
Various single center registries also reported the efficacy of DES for multivessel 
disease (66, 67). Because restenosis was the determining factor favoring surgery in 
previous randomized clinical trials comparing PCI to CABG, PCI with DES may be 
the first choice in many patients in the future, but randomized trials should confirm 
this approach. However, CABG is compelling for patients with left main disease or 
more diffuse coronary artery disease or specific high-risk patient subgroups (ie, 
multivessel disease with left ventricular dysfunction and diabetics), whereas patients 
with less diffuse disease and focal lesions are good candidates for PCI (68, 69).
ICD implantation
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Primary prevention of sudden cardiac death after myocardial infarction by an 
Implantable Cardioverter Defibrillator (ICD) was particularly studied in MADIT II and 
DINAMIT (70, 71). MADIT II demonstrated that in patients with a history of 
myocardial infarction who had reduced LV function (ejection fraction lower than 30%) 
there was a significant mortality reduction after implantation of an ICD. In DINAMIT, 
patients were randomised 6-40 days after myocardial infarction, in those with signs of 
reduced LV function and impaired autonomic tone. Although in DINAMIT a significant 
reduction of arrhythmogenic death was observed in patients randomised to ICD (HR
0.42, 95% CI 0.22-0.83), risk of non-arrhythmogenic death was increased in these 
patients, resulting no significant mortality difference between the treatment groups. 
Current guidelines advice to implant an ICD after 30 days in those patients who have 
an ejection fraction lower than 30%.
In the more recently published IRIS trial, benefit of ICD after STEMI was studied in 
patients with a reduced left ventricular ejection fraction (< or = 40%) and a heart rate 
of 90 or more beats per minute on the first available electrocardiogram (ECG) 
(criterion 1: 602 patients), nonsustained ventricular tachycardia (> or = 150 beats per 
minute) during Holter monitoring (criterion 2: 208 patients), or both criteria (88 
patients). In this study, prophylactic ICD therapy did not reduce overall mortality (72). 
The ongoing DAPA trial, will assess benefit of ICD in patients after primary PCI and 
TIMI flow less than 3 or left ventricular ejection fraction lower than 30% as measured 
short after admission for the index MI (73). Patients will be randomized between 30 
and 60 days after their MI.
The future
Although treatment of STEMI has improved during the last decades, in several fields 
additional improvement should be achieved. Strategies should be applied for 
reducing time to diagnosis, reducing time from diagnosis to arrival in a PCI center 
and decreasing door-to-balloon time in all patients. Randomized trials should 
demonstrate the most optimal combination of medical treatment given before arrival 
in the hospital. In patients with primary PCI, bleeding should be further decrease, 
possibly by use of newer agents as bivalirudin rather than heparin combined with GP 
2B/3A inhibitors. It should be clarified for how long agents as clopidogrel must be 
used to prevent risk of stent thrombosis, particularly in patients with drug eluting 
stents. After reperfusion therapy, much more patients should receive appropriate
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medication, including beta blockers, ACE inhibitors and statins. Before discharge, 
more intensive strategies for long-term life style modification should be initiated, 
including smoking cessation and weight reduction by both diet and physical exercise. 
Finally, additional studies should make clear which patients when should be treated 
with (prophylactic) ICD (74).
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Abbreviations and acronyms:
ACS: Acute Coronary Syndromes
CABG: Coronary Artery Bypass Graft
CHD: Coronary Heart Disease
CVD: cardiovascular disease
IABP: Intra-aortic balloon counterpulsation
MI: Myocardial Infarction
MPI: Myocardial Perfusion Imaging
MVD: Multi Vessel Disease
PCI: percutaneous coronary intervention
STEMI: ST-segment elevated myocardial infarction
TIMI: Thrombolysis in Myocardial Infarction trial
TLR: Target Lesion Revascularization
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ABSTRACT
Importance of the field: Inhibition of platelet aggregation plays a key role in treatment 
of coronary artery disease.
Areas covered in this review: Studies on the effects of tirofiban in patients with either 
ST elevation or non-ST elevation myocardial infarction are reviewed.
Main findings: Tirofiban is a small molecule glycoprotein IIb/IIIa receptor inhibitor. If 
discontinued, the action of tirofiban is faster reversed as abciximab. The dose varied 
between low (bolus of 0.4 Mg/kg administered over 30 minutes followed by an 
infusion of 0.10 Mg/kg/min), intermediate (bolus of 10 Mg/kg administered over 
3minutes followed by an infusion of 0.15Mg/kg/min) and high (bolus of 25 Mg/kg 
administered over 3 minutes followed by an infusion of 0.15Mg/kg/min). Especially the 
high dose administration, may be beneficial in patients with ST Elevation Myocardial 
Infarction undergoing primary PCI. There is no indication for tirofiban in patients 
treated with thrombolysis. Patients with Non-ST Elevation Myocardial Infarction 
requiring PCI are most likely to achieve benefit from tirofiban, when they have 
ongoing ischemia and/or dynamic ECG changes. The risk of serious bleeding, with 
tirofiban is low and there is a very low risk of thrombocytopenia.
Take home message: Use of tirofiban for myocardial infarction, is effective and has 
an acceptable safety profile.
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DRUG SUMMARY BOX
Drug name Tirofiban hydrochloride
Phase Launched
Launched indication Myocardial infarction 
Unstable angina 
Acute coronary syndrome
Pharmacology description GPIIb IIIa receptor antagonist 
Platelet aggregation antagonist
Route of administration Parenteral, intravenous
Chemical structure
Pivotal trial(s) ON-TIME2 shows effects of high-dose 
tirofiban in ST elevation infarction treated 
with primary PCI
PRISM-PLUS shows effects of tirofiban in 
non-ST elevation myocardial infarction 
COMPARE trial shows the importance of 
pharmacodynamics of the different GP 
IIb/IIIa inhibitors, including tirofiban
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1. MYOCARDIAL INFARCTION
Cardiovascular disease still generates a substantial burden of illness in many parts of 
the world. Acute coronary syndrome (ACS) is the umbrella term for the clinical signs 
and symptoms of acute myocardial ischemia resulting in unstable angina, non-ST- 
segment elevation myocardial infarction (non-STEMI) or ST-segment elevation 
myocardial infarction (STEMI). It is the clinical manifestation of severe myocardial 
ischemia due to an acute atherothrombotic coronary obstruction developed on the 
surface of a ruptured atheromatous plaque or as a consequence of endothelial 
erosion. Reperfusion therapy (either mechanical or pharmacologic) is indicated for 
patients with chest pain with a duration of 12 hours or less in association with ST- 
segment elevation with 1 mm of ST change (0.1 mV) in at least 2 contiguous limb 
leads (II, III, AVF, I,AVL), or 2 mm of ST change in at least 2 contiguous chest leads 
(V1-V6) or a new (or presumed new) left bundle-branch block. In comparison with 
conservative management (medical treatment without reperfusion therapy), 
fibrinolytic therapy improves left ventricular systolic function and survival in patients 
with myocardial infarction associated with either ST-segment elevation or left bundle- 
branch block. However, primary percutaneous coronary intervention (PCI) restores 
angiographically normal flow, including optimal TIMI 3 flow and blush, in the 
previously occluded artery in more than 90% of patients, whereas fibrinolytic therapy 
does so in only 50 to 70% of such patients. Therefore, primary PCI should be a 
preferred therapy in the majority of STEMI patients.
2. GLYCOPROTEIN IIB/IIIA INHIBITORS
Platelet thrombus formation has been shown to play an important role in the 
pathogenesis of ACS, and it is therefore not surprising that antiplatelet medication 
has become very important in the treatment of patients with ACS. Many trials have 
shown that oral antiplatelet treatment with aspirin and clopidogrel in these patients is 
not enough. A number of studies have investigated potential benefits of GP I Ib/IIIa 
inhibitors in patients with primary PCI for STEMI, including a significant reduction of 
the combined endpoint of death and recurrent myocardial infarction (1).
3. TIROFIBAN
Tirofiban is an intravenously administered nonpeptide tyrosine derivative that causes 
competitive GP IIb/IIIa receptor inhibition. It has a reversible, high specifici affinity for
43
the GP IIb/IIIa receptor. The platelet aggregation inhibition of tirofiban is immediate, 
extensive, and additive to oral treatment with aspirin and clopdiogrel. In a study 
among 100 patients with non-STEMI, it was demonstrated that tirofiban provided 
consistent and effective inhibition of platelet aggregation at the time of immediate or 
very early invasive therapy in contrast to only the combination of aspirin and 
clopidogrel (2). It was also shown that low-risk patients according to clinical 
presentation who had poor responsiveness to standard oral platelet inhibitors (aspirin 
and clopidogrel) as measured by a point-of-care assay, intensified platelet inhibition 
with tirofiban lowered the incidence of myocardial infarction after elective coronary 
intervention (3). There are probably no major differences in platelet inhibition 
between tirofiban and abciximab during PCI, although it was suggested that tirofiban 
has a greater inhibition in patients with diabetes (4). Probably, tirofiban also 
decreases the inflammatory reactions in patients with acute coronary syndrome (5), 
but not in patients with PCI for stable angina (6).
The dose of tirofiban varied between low (bolus of 0.4 Mg/kg administered over 30 
minutes followed by an infusion of 0.10 Mg/kg/min), intermediate (bolus of 10 Mg/kg 
administered over 3minutes followed by an infusion of 0.15Mg/kg/min) and high 
(bolus of 25 Mg/kg administered over 3 minutes followed by an infusion of
0.15Mg/kg/min). The half-life of tirofiban is 2 -4  hours, and therefore adenosine 
diphosphate (ADP)-induced platelet aggregation returns to near-baseline levels 
within 4 to 8 hours after cessation of a tirofiban infusion. Tirofiban is renally cleared 
and thus must have dosage adjustment if used in patients with renal insufficiency. 
Half-dose tirofiban is recommended in patients with creatinin clearance < 30 ml/min.
4. ADVERSE REACTIONS TO TIROFIBAN
Tirofiban is generally well tolerated. Bleeding complications are the most commonly 
reported events associated with tirofiban in clinical trials, but the rate of major 
bleeding in tirofiban recipients was not significantly different from that reported with 
heparin. Thrombocytopenia (platelet count < 90,000 cells/microliter) can be caused 
by all GP IIb/IIIa inhibitors, but occur with tirofiban less frequently than with abciximab 
(7). The underlying mechanism of glycoprotein IIb/IIIa inhibitor-induced 
thrombocytopenia is probably an immune-mediated reaction, with the presence of 
circulating antibodies against IIb/IIIa antagonists (8).
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5. TIROFIBAN FOR ST-ELEVATION MYOCARDIAL INFARCTION 
The initial beneficial effects of GP IIb/IIIa inhibitors in patients with primary PCI for 
STEMI were demonstrated with abciximab. Although some trials failed to 
demonstrate improvement (9), meta-analyses have shown clearly their benefits (10). 
Another meta-analyses showed that among STEMI patients undergoing primary PCI 
similar results can be observed between abciximab and small molecules (tirofiban, 
eptifibatide) in terms of angiographic, electrocardiographic, and clinical outcome (9, 
10). Although early studies with low or intermediate dose tirofiban showed less clear 
results (13), more recent studies, using high-dose bolus tirofiban, support its 
beneficial effects in patients with STEMI undergoing primary PCI (14, 15). In the 
MULTISTRATEGY randomized trial, including 745 patients with STEMI undergoing 
percutaneous coronary intervention, compared with abciximab, high-dose tirofiban 
therapy was associated with noninferior resolution of ST-segment elevation at 90 
minutes following coronary intervention (16). An early ischemic hazard disfavoring 
tirofiban was suggested when compared with abciximab in studies based on 10 but 
not 25 microg/kg tirofiban bolus regimen (17).
Early administration of GP IIb/IIIa inhibitors (during transport to the hospital) seems 
even more attractive for the potential benefits expected from early recanalisation, 
which might overcome any potential delay to mechanical reperfusion. A meta­
analysis published in 2008 showed that early administration of GP IIb/IIIa inhibitors is 
associated with significant benefits in terms of preprocedural epicardial 
recanalisation, improved myocardial perfusion and less distal embolisation but not 
into significant benefits in survival (18). The On-Time 2 study investigated the effect 
of high-dose tirofiban as administered in the ambulance as compared to high-dose 
tirofiban given in the hospital (19). At the time of arrival to the PCI centre, patients 
treated with tirofiban had significantly lower cumulative residual ST-segment 
deviation than those who received placebo (10.9- 9.2mmvs 12.1- 9.4mm; p= 0.028). 
ST-segment resolution prior to PCI (aborted infarction) occurred significantly more 
often in the tirofiban arm (p = 0.041 for trend), resulting in a better net clinical 
outcome. The cumulative residual ST-segment deviation 1 hour post-PCI (primary 
endpoint) was 3.6 -  4.6mm for the tirofiban group versus 4.8 -  6.3mm in the placebo 
group (p = 0.003). Furthermore, the percentage of patients with more than 3mm 
residual ST-segment deviation was significantly lower in the tirofiban than the 
placebo arm (36.6% vs 44.3%; p = 0.026). Also significant reduction in stent
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thrombosis has been shown after prehospital administration of tirofiban, as compared 
to placebo (20). These results confirm the On-Time-1 randomized trial (21), that has 
shown that early administration of tirofiban is associated with a better patency (TIMI 2 
or 3 flow), a lower prevalence of thrombus or fresh occlusion and a better myocardial 
perfusion in the infarct-related region pre-PCI, as compared to late administration of 
tirofiban. In contrast, the potential beneficial effects of only bail out administration of 
GP IIb/IIIa inhibitors in patients with STEMI (indicated by suboptimal flow, distal 
embolisation or side branch occlusion) is less clear (22). In conclusion, in patients 
undergoing primary PCI for STEMI, tirofiban should be given early after symptom- 
onset (either at home or in the ambulance) rather than upon cathlab arrival. Since it 
has been shown that prasugrel is more effective than clopidogrel for prevention of 
ischaemic events, without an apparent excess in bleeding in patients with STEMI 
(23), it should be assessed whether GP IIb/IIIa inhibitors in patients pretreated with 
pasugrel are still of additive benefit.
Several studies have assessed the combination of GP IIb/IIIa inhibitors with 
thrombolysis, using either standard doses of thrombolytic agents (TAMI 8, IMPACT- 
AMI, GUSTO V and PARADIGM) or reduced dosages of thrombolytic agents (TIMI
14, FINESSE and SPEED) for combination therapy. In the BRAVE study, early 
administration of reteplase plus abciximab did not lead to a reduction of infarct size 
compared with abciximab alone in patients with acute STEMI referred for PCI (24). 
Although most studies were performed with abciximab, some were done with tirofiban 
(25) or eptifibatide (26). One of the concepts of the combination of thrombolytics and 
GP IIb/IIIa inhibitors was to have an optimal pharmacological combination for 
facilitated (primary) PCI. However, current evidence does not support the routine use 
of combination of reduced-dose thrombolytic and GP IIbIIIa inhibitor therapy- 
facilitated PCI for the treatment of STEMI. In addition, this combined therapy has 
been shown to be associated with an increased risk of major bleeding complications. 
Small studies suggested beneficial effects of GP IIb/IIIa inhibitors in patients 
undergoing rescue PCI after failed thrombolysis, without a significant increase in 
bleeding or vascular complications (27,28).
The Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial 
Infarction (HORIZONS-AMI) trial demonstrated a significantly lower mortality and 
bleeding event rate after on year in favor of bivalirudin monotherapy (with provisional 
GP IIb/IIIa receptor blockade) in comparison with unfractionated heparin plus GP
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IIb/IIIa blockade in patients undergoing primary PCI for STEMI (29), However, 
bivalirudin monotherapy was associated with a highly significant greater incidence of 
acute stent thrombosis. More randomized trials should confirm these observations, 
and also potential benefits of bivalirudin given in the ambulance.
6. TIROFIBAN FOR NON ST-ELEVATION MYOCARDIAL INFARCTION 
Glycoprotein IIb/IIIa inhibitors reduce the occurrence of death or myocardial infarction 
in patients with acute coronary syndromes, with the greatest event reduction in 
patients at high risk of thrombotic complications (20). Therefore, current practice 
guidelines recommend administering a platelet glycoprotein IIb/IIIa inhibitor, in 
conjunction with aspirin and heparin, for patients with non-ST segment elevation 
myocardial infarction for whom an early invasive management strategy is indicated. 
Although there was no benefit of abciximab in GUSTO-IV ACS, this was probably 
caused by the variable recovery of platelet aggregation with continued (24-48 hours) 
abciximab infusion before PCI as was performed in this trial (31). The negative 
results of the GUSTO IV-ACS trial may be also explained by the lack of access to 
timely revascularization which is in keeping with the results of several other trials 
based on the use of GPIIb/IIIa inhibitors. Also a more recent trial, among high-risk 
patients with an elevated troponin level, found that the incidence of events was 
significantly lower with concurrently administered clopidogrel and abciximab (13.1%) 
than clopidogrel and placebo (18.3%) (32), making clear that results of GUSTO IV- 
ACS should be interpreted cautiously.
In PRISM-PLUS, a study involving 1915 patients with unstable angina/non-Q- 
wave MI, administration of intravenous tirofiban (0.4 microgram/kg/min loading dose 
for 30 minutes followed by a 0.10 microgram/kg/min infusion) with heparin for at least 
48 (mean 71.3) hours reduced the 7-day risk of the composite end-point of MI, death 
and refractory ischemia by 32% compared with heparin alone (33). There haven 
been discussion about the optimal dose of tirofiban in patients with non-STEMI. In 
vitro studies show clearly more complete platelet aggregation inhibition with higher 
doses tirofiban (34). Contrary, tirofiban does not achieve >80% platelet aggregation 
inhibition at the time of PCI at a dose of 10 microg/kg bolus plus 0.15 microg/kg/min 
infusion, and at a dose of 0.4 lg/kg/min loading infusion for 30 minutes plus 0.1 
microg/kg/min maintenance infusion, the target value is only reached after 18 h (35,
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36). These pharmacodynamic observations may explain the excess periprocedural 
thrombotic events reported with the low dose tirofiban regimen compared with 
abciximab in TARGET (37). This may be also an explanation of the beneficial effects 
of tirofiban in patients with non-STEMI if PCI is delayed until 4 to 48 hours after drug 
initiation (38).
There has also been debate about the optimal timing of glycoprotein IIb/IIIa inhibitor 
administration in patients with non-STEMI: 'upstream' in the coronary care unit or 
'downstream' when the patient goes to the catheterization laboratory, although this 
may have been influenced by too low loading doses. Results of the EVEREST pilot 
study, a mechanistic study evaluating epicardial and tissue level perfusion and 
cardiac troponin I release, significantly favored upstream administration of tirofiban 
over downstream glycoprotein IIb/IIIa inhibitor for high-risk patients with NSTE ACS 
undergoing PCI (39). Moreover, high bolus dose tirofiban or abciximab administered 
just before PCI produced similar effects on angiographic outcome and cardiac 
troponin I release in this study. However, the EARLY-ACS study demonstrated that 
glycoprotein IIb/IIIa inhibitors should be initiated at the time of angiography and that 
their routine administration 12 to 24 hours before the procedure can cause an 
increased risk of bleeding and no improvement in outcome (38). Previously, this was 
also observed in the ACUITY trial (41).
EXPERTS OPINION
Administration of tirofiban in patients with myocardial infarction, either with or without 
ST elevation, is effective if an invasive approach is followed. The earlier tirofiban is 
administered after symptom onset, the more clear the beneficial effects in patients 
with STEMI. For this reason, we recommend that for patients with STEMI, tirofiban 
should be given early, before hospital arrival, either at home, in the ambulance, or in 
the referral hospital. Because the results of the high-dose tirofiban administration 
(bolus of 25 Mg/kg administered over 3 minutes followed by an infusion of
0.15Mg/kg/min) are more effective, without significant bleeding complications, we 
recommend to use the high dose. However, although existing results are promising, 
there are less trial data with high-dose tirofiban compared to other GP IIb/IIIa 
inhibitors, and results of initial trials should be confirmed. In patients treated with 
thrombolysis, there is no additional value for GP IIb/IIIa inhibitors. In non-STEMI, 
timing of administration of tirofiban, either at the coronary care unit or just before
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angiography is less clear, but with the high dose regimen, administration just before 
angiography may become the choice.
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CHAPTER 4
Impact of stenting on Mortality in Patients 
undergoing Primary PCI for ST-Elevation 
Myocardial Infarction
ESC congress review 2009:58-63
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Abstract
Purpose: Although in patients with primary percutaneous coronary intervention (PCI) 
for ST elevation Myocardial Infarction (STEMI), stenting seems to be associated with 
a reduced risk of reinfarction and target vessel revascularization, it is less clear 
whether stenting reduces mortality when compared to balloon angioplasty. To assess 
the potential association between mortality and stenting in primary PCI in daily 
practise, analyses of a prospective registry were performed.
Methods: A large scale, prospective, observational study was performed between 
1991 and 2004 of all consecutive STEMI patients who underwent primary PCI. 
Results: Primary PCI was performed in 4299 patients, of whom 2571 patients 
(59.8%) were treated by (bare metal) stenting. There were no differences in age, 
gender, infarct location or diabetes between the two groups. Patients in the balloon 
group had more often previous myocardial infarction and multi vessel disease, and 
had a longer duration between symptom start and admission. The combined end­
point of death or re-infarction after 30 days was 7.2% in the balloon group vs 5.6% in 
the stent group (p=0.03). After one year follow-up, mortality in the balloon group was 
7.9%, compared to 5.8% in the stent group (p=0.007). After adjusting for differences 
in age, gender, previous myocardial infarction, patient delay and multi vessel 
disease, use of a stent was still associated with a decreased risk of one-year 
mortality, with OR 0.77, 95% CI 0.61 -  0.98.
Conclusion: In patients undergoing primary PCI for STEMI, use of stents in daily 
practise is associated with a decreased mortality.
Introduction
Primary percutaneous coronary intervention (PCI) is very effective in restoration of 
coronary blood flow in the infarct related vessel of patients with ST elevation 
myocardial infarction (STEMI). However, recurrent ischemia occurs in a substantial 
part of patients, resulting in silent or clinically apparent reocclusion of the infarct 
related vessel and the need for subsequent target vessel revascularization. To treat 
the significant risk of coronary flow-limiting dissections and restenosis during the first 
six months following a PCI, two main studies comparing percutaneous transluminal 
coronary angioplasty and coronary stenting (STRESS and BENESTENT) performed 
in 1994 showed a significant reduction in restenosis after using stents (1, 2).
57
Although a number of randomised controlled trials has shown that stenting during 
primary PCI may decrease target vessel revascularization and recurrent myocardial 
infarction, there was no clear decrease of mortality after stenting (3, 4). Moreover, the 
randomised trials excluded many patients, most had a limited sample size, and 
interpreting results was difficult because of cross-over. To assess the potential 
association between mortality and stenting in patients undergoing primary PCI, 
analyses of a prospective registry were performed.
Methods
Population
From January 1991 to December 2004, individual patient data from all patients with 
diagnosis of STEMI who were admitted for primary PCI at the Isala klinieken (Zwolle, 
the Netherlands) were prospectively recorded. To avoid double inclusion of patients, 
only the first recorded admission for STEMI during the study period was used. Before 
angiography all patients received 300-500 mg of aspirin intravenously. Till 1999, a 
bolus of 10.000 IU intravenous unfractionated heparin (high dose UFH group) was 
given as adjunctive therapy. Since then, the total bolus of intravenous UFH was 
decreased to 5.000 IU (low dose UFH group). In addition to aspirin and heparin, 
clopidogrel was given 300mg orally since 1999. Primary PCI was performed with 
standard techniques if the coronary anatomy was suitable for angioplasty. Success of 
the PCI was determined by the classification system of the Thrombolysis in 
Myocardial Infarction (TIMI) trial, in which a grade 3 blood flow indicates normal flow 
within the vessel, in combination with a myocardial blush grade 2 or 3. Additional 
treatment with stents was left to the discretion of the treating cardiologist. All patients 
were treated with optimised drug-therapy including angiotensin-converting enzyme 
inhibitors, p-blockers and lipid-lowering drugs where appropriate.
Measurements (end points, definitions)
Patients were diagnosed with STEMI if they had chest pain of > 30 minutes duration 
and ECG changes with ST segment elevation > 2 mm in at least 2 precordial and > 1 
mm in the limb leads. Recurrent myocardial infarction was diagnosed when there was 
a 50 percent decrease of creatine kinase-muscle-brain fraction (CK-MB) from a 
previous peak value, followed by a subsequent rise to a level exceeding the upper 
limit of normal.
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Protocol-specified blood sampling for creatine kinase (CK) and its muscle-brain 
fraction (CK-MB) levels was performed at baseline and at 8 hours, 16 hours and 24 
hours after PCI. Measurement of serum total CK and CK-MB levels was performed 
according to local hospital standards. Left ventricular ejection fraction was measured 
before discharge by radionuclide ventriculography or by echocardiography if the 
patient had atrial fibrillation. Radionuclide ventriculography was performed by using 
the multiple gated equilibrium method following the labelling of red blood cells of the 
patient with 99mTc-pertechnate. A General Electric 300 gamma camera with a low- 
energy all-purpose parallel-hole collimator was used. Global ejection fraction was 
calculated by a General Electric Star View computer using the fully automatic PAGE 
program. In patients with atrial fibrillation, standard 2-dimensional and Doppler 
imaging was performed and stored in cineloop format by well-trained 
echocardiographists and reviewed by experienced cardiologists who estimated the 
ejection fraction by visual assessment.
Data collection and follow-up
We collected the following variables from the patient files: age, gender, history of 
hypertension, diabetes, hyperlipidemia, smoking, previous myocardial infarction, Killip 
class on admission, angiographic variables, laboratory measurements, major- and 
minor bleeding, pre-discharge LV function and discharge medication. Follow-up 
information was obtained from the patient's general physician or by direct telephone 
interview with the patient. Study approval was obtained from the medical ethic 
committee of our hospital.
Statistical Analysis
Statistical analysis was performed with the Statistical Package for the Social 
Sciences (SPSS Inc., Chicago, IL, USA) version 15.0.1. Continuous data were 
expressed as mean ± standard deviation and categorical data as percentage, unless 
otherwise denoted. Differences between continuous data were performed by 
student’s t test and the chi-square or Fisher’s exact test was used as appropriate for 
dichotomous data. Multivariable logistic regression analysis was performed to test the 
independent association between one year mortality and use of a stent. Significant 
variables analyzed are reported with their respective odd ratios and 95% confidence 
intervals. Cox proportional-hazards regression models were used to estimate hazard
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ratios of patients with a stent with regard to survival at one year. Survival was 
represented by Kaplan-Meier curves. For all analyses, statistical significance was 
assumed when the two-tailed probability value was < 0.05.
Results
Baseline characteristics
During the study period, 5030 patients were admitted with STEMI (figure 1). After 
excluding patients who were not treated by primary PCI, and those with missing data, 
a total of 4299 patients were included in the analysis, of whom 2571 patients (59.8%) 
were treated by (bare metal) stenting.
Baseline characteristics of the study population are summarized in table 1. There 
were no differences in age, gender, infarct location or diabetes between the two 
groups. Patients in the balloon group had more often previous myocardial infarction 
and multi vessel disease, and had a longer duration between symptom-onset and 
admission. Use of glycoprotein IIb/IIIa inhibitors was comparable between the two 
groups.
End points
The combined end-point of death or re-infarction after 30 days was 7.2% in the 
balloon group vs 5.6% in the stent group (p=0.03). After one year follow-up, mortality 
in the balloon group was 7.9%, compared to 5.8% in the stent group (p=0.007). The 
combined end point of dead, myocardial infarction or re-intervention after one year 
was 22.6% in the balloon group compared to 20.0% in the stent group (p=0.04).
After adjusting for differences in age, gender, previous myocardial infarction, patient 
delay and multi vessel disease, use of a stent was still associated with a decreased 
risk of one-year mortality, with OR 0.77, 95% CI 0.61 -  0.98.
Discussion
In this prospective registry of patients treated with primary PCI for STEMI, we found 
that use of a stent was independently associated with a lower one-year mortality rate. 
Also the one-year combined end point of death, recurrent myocardial infarction and 
recurrent revascularisation was lower after stenting, as compared to balloon group.
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The first randomised trials demonstrating the benefits of primary PCI for STEMI as 
compared to thrombolysis were published in the early 90s (5-7). Balloon angioplasty 
was the principal mode of performing PCI in these first years. Nowadays, stent 
implantation is mostly performed. A total of 13 randomised trials have been 
performed comparing balloon with stent for STEMI (4). Although stenting was not 
associated with a significant reduction in 30-day or 1-year mortality (5.1% versus 
5.2%, p=0.81), as compared to balloon angioplasty, stenting was associated with 
benefits in terms of target vessel revascularisation at both 30-day and 6 to 12 
months.
In general, stent implantation is effective in both the management of (iatrogenic) 
coronary dissection during PCI and reduces restenosis. The immediate effective 
treatment of dissections and occlusion after balloon coronary angioplasty by stents 
has reduced the need for emergent bypass surgery (8, 9).
Although randomised trials have shown that stenting in patients with STEMI were 
particularly associated with a decreased risk of target vessel revascularisation, the 
mortality rate in our study was also lower in the stent group, as compared to balloon 
angioplasty. Compared to randomised trials, the mortality benefit after stenting in our 
study could be explained as follows: First, in the randomised trials, many patients in 
the balloon group had cross-over to stent. Secondly, in the randomised trials several 
(high-risk) groups were excluded. Finally, most trials had only a limited number of 
patients and were not powered to demonstrate mortality differences.
Innovations after bare metal stents
After the introduction of stents, several efforts have been made to further reduce the 
incidence of re-stenosis. Beta and gamma intracoronary brachytherapy has been 
shown to be more efficacious than placebo in reducing death, myocardial infarction, 
and target vessel revascularization at long-term follow up of patients with in-stent 
restenosis (10). However, limitations of brachytherapy include forming of aneurysms 
and late stent occlusion (11, 12). Aloso ,increased late lumen loss at the stent edges, 
also known as the "candy wrapper" phenomenon, may occur (13).
An important advantage in interventional cardiology was the introduction of drug 
eluting stents. Benefits of drug eluting stents in reducing restenosis have clearly been 
shown in many randomized trials. An epidemiological study has also shown that after
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the widespread adoption of drug-eluting stents into routine practice, a decline in the 
need for repeat revascularization procedures could be observed (14). However, the 
effects on major adverse cardiac events (death, myocardial infarction) are less clear 
(15). Another limitation of drug eluting stents is that they are associated with an 
increased risk of stent thrombosis as compared to bare metal stents (16). This 
increased risk may also exist after one year of implantation (17). However, also in the 
setting of STEMI, several prospective randomised trials and meta-analyses have 
shown the superiority of drug eluting stents as compared to bare metal stents in 
terms of target vessel revascularisation, with similar rates of death, reinfarction, and 
stent thrombosis (18, 19).
Limitations of the current analysis
Although this study included a large cohort of all comers undergoing primary PCI for 
STEMI, it concerned a non-randomised registry in patients treated by bare-metal 
stents only. Therefore the results should be interpreted with this in mind.
Furthermore, we had no data on medication during follow-up. Particularly aggressive 
cholesterol lowering drugs may be associated with less restenosis. There may have 
been a difference between patients with and without a stent regarding use of 
clopidogrel. Possibly, patients with a stent had (longer) treatment with clopidogrel, 
which could have introduced bias.
Conclusions
After multivariable analyses, the use of stent for STEMI in daily practise is associated 
with a decreased risk of one-year mortality.
62
1. Kiemeneij F, Serruys PW, Macaya C, et al. Continued benefit of coronary 
stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I 
trial. J Am Coll Cardiol. 2001;37:1598-603.
2. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of 
coronary-stent placement and balloon angioplasty in the treatment of coronary 
artery disease. N Engl J Med. 1994;331:496-501.
3. Nordmann AJ, Bucher H, Hengstler P, Harr T, Young J. Primary stenting 
versus primary balloon angioplasty for treating acute myocardial infarction. 
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD005313.
4. De Luca G, Suryapranata H, Stone GW, Antoniucci D, Biondi-Zoccai G, 
Kastrati A, Chiariello M, Marino P. Coronary stenting versus balloon 
angioplasty for acute myocardial infarction: a meta-regression analysis of 
randomized trials. Int J Cardiol. 2008 May 7;126(1):37-44.
5. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. 
A comparison of immediate coronary angioplasty with intravenous 
streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.
6. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty 
with thrombolytic therapy for acute myocardial infarction. N Engl J Med 
1993;328:673-679.
7. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh 
BJ. Immediate angioplasty compared with the administration of a thrombolytic 
agent followed by conservative treatment for myocardial infarction. N Engl J 
Med 1993;328:685-691.
References
63
8. Hearn JA, King SB 3rd, Douglas JS Jr, Carlin SF, Lembo NJ, Ghazzal ZM. 
Clinical and angiographic outcomes after coronary artery stenting for acute or 
threatened closure after percutaneous transluminal coronary angioplasty.
Initial results with a balloon-expandable, stainless steel design. Circulation. 
1993 Nov;88(5 Pt 1):2086-96.
9. Roy P, de Labriolle A, Hanna N, et al. Requirement for emergent coronary 
artery bypass surgery following percutaneous coronary intervention in the 
stent era. Am J Cardiol. 2009;103:950-3.
10. Saleem MA, Aronow WS, Ravipati G, et al. Intracoronary brachytherapy for 
treatment of in-stent restenosis. Cardiol Rev. 2005;13:139-41.
11. Bal ET, Plokker T, van den Berg EMJ, Ernst SMPG, Mast EG, Gin RMTJ et al. 
Predictability and prognosis of PTCA-induced coronary aneurysms. Cathet 
Cardiovasc Diagn 1991;22:85-88.
12. Costa M, Sabaté M, van der Giessen WJ, Kay IP, Cervinka P, Ligthart JM et 
al. Late coronary occlusion after intracoronary brachytherapy. Circulation 
1999;100:789-92.
13. Serruys PW, Kay IP. I like the candy, I hate the wrapper: the (32)P radioactive 
stent. Circulation 2000;101:3-7.
14. Malenka DJ, Kaplan AV, Lucas FL, Sharp SM, Skinner JS. Outcomes 
following coronary stenting in the era of bare-metal vs the era of drug-eluting 
stents. JAMA. 2008;299:2868-76.
15. Al Suwaidi J, Holmes DR Jr, Salam AM, Lennon R, Berger PB. Impact of 
coronary artery stents on mortality and nonfatal myocardial infarction: meta­
analysis of randomized trials comparing a strategy of routine stenting with that 
of balloon angioplasty. Am Heart J. 2004;147:815-22.
64
16. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and 
paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008.
17. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late 
thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. 
Am J Med. 2006;119:1056-61.
18. Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for 
acute myocardial infarction. N Engl J Med. 2008;359:1330-42.
19. De Luca G, Valgimigli M, Spaulding C, Menichelli M, Rocca HP, van der 
Hoeven BL, Di Lorenzo E, de la Llera LS, Pasceri V, Pittl U, Percoco G, Violini 
R, Stone GW. Short and long-term benefits of sirolimus-eluting stent in ST- 
segment elevation myocardial infarction: a meta-analysis of randomized trials. 
J Thromb Thrombolysis. 2009 Feb 4. [Epub ahead of print]
65
Acronyms and Abbreviations: MI: myocardial infarction; LMWH: low-molecular- 
weight heparin; PCI: percutaneous coronary intervention; STEMI: ST-segment 
elevated myocardial infarction;
Legend of figures
Figure 1: Flow chart of analysis
Figure 2: Effects of use of stents vs balloon on different end points
Figure 3: One year mortality curves of stent (-------- ) versus
balloon ( __________ )
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Table I: General characteristics according to use of stent in 4299 patients who
were treated by primary PCI for ST-elevation MI
Balloon 
N = 1728
Stent 
N =2571
P value
% or mean ± SD % or mean ± SD
Age (years) 61.4 ± 11.7 60.9 ± 11.9 0.15
Female gender 25.3 23.2 0.11
History of:
Myocardial Infarction 14.9 9.4 <0.001
Coronary Bypass Surgery 2.9 2.3 0.21
Stroke 3.6 3.2 0.47
Hypertension 29.5 29.4 0.94
Diabetes 10.8 10.6 0.81
Hypercholesterolaemi a 22.5 21.9 0.67
Family history of coronary 42.1 42.6 0.76
artery
disease
Anterior location 49.6 48.8 0.62
Ischemic time (hours) 4.1 ± 5.4 3.7 ± 4.4 0.003
Admission glucose (mmol/L) 9.7 ± 3.7 9.6 ± 3.6 0.65
Admission CK (U/L) 709 ± 1225 690 ± 1158 0.61
Multi Vessel Disease 57.3 49.3 <0.001
Use of Glycoprotein IIb/IIIa 57 60 0.26
inhibitor
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Table II: Outcome according to use of stent in 4299 patients who were treated
by primary PCI for ST-elevation MI
Balloon 
N = 1728
Stent 
N =2571
P value
% or mean ± SD % or mean ± SD
TIMI 3 flow post PCI 86.4 90.7 <0.001
Peak creatine kinase (IU/L) 2445 ± 3042 2627 ± 2376 >0.001
Left Ventricular Ejection 0.38
Fraction 44.7 ± 11.6 45.1 ± 12.2
Mortality
30 days 5.0 3.3 0.05
One year 7.9 5.8 0.007
Death/recurrent infarction
30 days 7.2 5.6 0.03
One year 11.7 10.0 0.08
Death/recurrent infarction/ 22.6 20.0 0.04
recurrent
PCI within one year
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CHAPTER 5
Comparison of Rapamycin and Paclitaxel Eluting Stents in Patients 
Undergoing Primary Percutaneous Coronary Intervention for ST
Elevation Myocardial Infarction
Best coated stent for STEMI
Am J Cardiol 2009;104:205-9
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Abstract
As compared to Bare Metal Stent, Sirolimus (SES) and paclitaxel (PES) eluting 
stents have been shown to improve angiographic and clinical outcomes after 
percutaneous coronary intervention (PCI) in elective and ST elevation Myocardial 
Infarction (STEMI) patients. Aim of the current study was to compare SES to PES 
among STEMI patients undergoing primary PCI. Patients with STEMI were 
randomized 1:1 to receive the SES (n=196) or PES (n=201). Primary end point was 
late lumen loss at 9 months follow-up by quantitative coronary angiography. 
Secondary end points were major adverse cardiac clinical events (death, re­
infarction, target vessel revascularization) at 1, 9 and 12 months. A total of 397 
patients with STEMI were randomized. The two groups had comparable baseline 
clinical and angiographic characteristics. Mortality was low, 1.5% after 30 days, 2.3 % 
after 9 months and 3.1% after one year. There was no difference in any clinical 
outcome at any follow-up period between the two treatment groups. Follow-up 
angiography was completed in 272 of 397 patients (69 percent). The mean (SD) in­
stent late loss was 0.01 (0.42) mm in the sirolimus group vs 0.21 (0.50) mm in the 
paclitaxel group (difference, -0.20 mm, P 0.001). In conclusion: In patients with 
STEMI, primary PCI with SES results in less late loss compared to paclitaxel eluting 
stents. However, these benefits did not translate into significant reduction in MACE at 
one-year follow-up.
Keywords: drug-eluting stents, infarction
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Benefits of primary percutaneous coronary intervention (PCI) for ST elevation 
myocardial infarction (STEMI) have been demonstrated (1-3). However, recurrent 
ischemia occurs in 10 to 15% after initially successful PCI, and silent or clinically 
apparent reocclusion of the infarct related vessel (IRV) occurs in 5 to 10%, whereas 
angiographic restenosis is observed in 30 to 50% (4). As a result, the need for 
subsequent target vessel revascularization (TVR) in the first 6 months remains 
disappointingly high. Although stents may decrease restenosis and TVR (5-7), in­
stent restenosis, after initially successful stenting remains to be 20% to 50%, 
depending upon a number of risk factors and lesion characteristics. Drug-eluting 
stents reduce angiographic and clinical measures of restenosis compared with bare- 
metal stents (8,9) in elective and STEMI patients. Sirolimus-eluting stents (SES) have 
been shown to be superior to paclitaxel-eluting stents (PES) in several trials in 
elective patients. However, only few data have been reported in primary PCI for 
STEMI. The aim of the current study is to compare SES and PES in patients 
undergoing primary PCI for STEMI.
METHODS
It concerns a prospective, single-centre (Isala klinieken, Zwolle, Netherlands), 
randomized controlled study involving 397 patients with STEMI, comparing the 
Sirolimus coated Cypher stent with the Paclitaxel coated Taxus stent. Patients were 
followed for a period of 12 months for evaluation of continued vessel patency, and 
the incidence of complications. There was no industry involvement in the design, 
conduct or analysis of the study. The study was approved by the local ethics 
committee. The study was registered, with number ISRCTN90526229. Written 
informed consent was obtained from all patients.
All patients with STEMI, presenting within 6 hours after symptom-onset, or those 
presenting between 6 and 24 hours if they had persisting chest pain associated with 
clinical evidence of on-going ischemia, were eligible if they had the culprit lesion in a 
native coronary artery, suitable for stenting, with a lesion length of < 30 mm and a 
vessel diameter > 2.5 mm. Exclusion criteria were women of child-bearing potential, 
severe hepatic or renal disease, previous participation in the study, life expectancy of 
< 1 year, factors making follow-up difficult, pre-treatment with thrombolysis, 
unprotected left main disease or single remaining vessel, target lesion in a bifurcation 
with a large side-branch, known sensitivity to aspirin, clopidogrel or coumarin, or
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patients who were unable to provide informed consent. All patients were pretreated 
with aspirin, a loading dose of clopidogrel and intravenous nitroglycerin and heparin. 
Treatment with glycoprotein IIB/IIIA inhibitors was left to the discretion of the 
physicians. Stenting of target lesion were performed using standard interventional 
techniques, without routinely post dilating the stents. After the primary PCI all patients 
were treated with current guidelines provided medication, including statins and beta­
blockers. All patients received clopidogrel for at least 6 months.
Angiography of the IRV was performed according to the standard acquisition 
procedures for QCA analysis. An independent angiographic core laboratory 
(DIAGRAM BV, Zwolle, the Netherlands) analyzed all preprocedural, periprocedural, 
and postprocedural angiographic images using edge detection techniques. 
Quantitative angiography was done in at least 2 orthogonal views. Intracoronary 
nitroglycerin was given prior to each series of angiograms if the patient was 
hemodynamic stable. The PCI procedure was considered completed once the 
guiding catheter was removed. Follow-up angiography at 9 months was performed 
corresponding to those settings used during the stenting procedure. Quantitative 
coronary angiography (QCA) was analyzed using the CAAS II system. Late lumen 
loss was defined as the minimal lumen diameter (MLD) immediately post PCI -  the 
MLD at follow-up angiography.
Primary endpoint was the late lumen loss at 9 months follow-up by quantitative 
coronary angiography. Secondary end points were major adverse cardiac clinical 
events (death, re-infarction, target vessel revascularization) at 1, 9 and 12 months. 
The study was designed to demonstrate superiority of the Cypher stent based on the 
assumption that at follow-up angiography the late loss was at least 0.15 mm smaller 
than the mean late loss when the Taxus stent was used. It was expected that in the 
Sirolimus eluting stent group the mean late loss would be 0.15 mm with a standard 
deviation of 0.50 mm. In a one-way ANOVA study, sample sizes of 176 patients per 
group were needed, resulting in a total sample of 352 subjects achieving 80% power 
to detect differences among the means versus the alternative of equal means using a 
F test with a 0.05 significance level. Distinction was made between the end points 
occurring during the procedure, early or late. Procedural events were defined as 
events occurring in the time interval between insertion of the arterial sheath and 
withdrawal of the sheath out of the patient. Early events were defined as events 
occurring between sheath removal and 1 month. Late events were defined as events
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occurring after 1 month. All other adverse events and malfunctions of stent and 
delivery system were reported descriptively. Reinfarction was defined by the 
presence of recurrent ischemic symptoms or electrocardiographic changes 
accompanied by a creatine kinase level that was more than twice the upper limit of 
the normal range (with an elevated MB isoform level) or more than 50 percent higher 
than the previous value obtained during hospitalization with or without stent 
thrombosis or development of Q waves. Stent thrombosis was defined as acute 
ischemic symptoms (typical chest pain with duration more than 20 min) accompanied 
by occlusion of the infarct related vessel, originating in the peri-stent region. 
Restenosis was defined as at least 50% reduction in diameter when compared to 
reference luminal diameter assessed by QCA in 2 orthogonal views. Repeat target 
lesion revascularization was performed if symptoms of angina and/or objective 
evidence of ischemia were documented.
Clinical and angiographic data were analyzed both according to the principle of intent 
to treat and evaluable group analyses. Comparability of treatment groups with 
respect to demographic and pre-treatment population characteristics were assessed 
using a one-way ANOVA F- or Wilcoxon Rank Sums Scores test, a chi-square test 
for two-way contingency tables, and a chi-square test for homogeneity of proportions, 
respectively. End-point variables were presented by 95% confidence intervals for the 
mean difference for quantitative results. An estimate of the relative risk for the 
treatment groups and the 95% confidence interval of the risk were provided for 9- 
month restenosis rate and each of the adverse event parameters.
The actuarial life table method was used for analyzing the occurrence of adverse 
events and target revascularization during the one-year follow-up period. Patients 
who died or who were lost to follow-up were censored at their last follow-up 
according to their clinical status at that time. In case appropriate P values for testing 
differences in survival curves were computed by means of the Wilcoxon as well the 
log rank test.
RESULTS
Patients were included between January 2005 and October 2007. A total of 397 
patients were included in the study. The baseline characteristics of the patients were 
comparable in the two randomized groups (table 1). Mean age was 61 years and 
8.6% of patients had diabetes. Baseline angiographic data are summarized in table
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2. Again, the variables were well matched between the two treatment groups, with in 
the sirolimus group a trend to more often use of only 1 stent. Due to technical 
reasons, we could not implant stents in 4 patients (3 in PES group and 1 in SES 
group).
The occurrence of clinical events up to one year is summarized in table 3. In the total 
group, the cumulative incidence of MACE (death, re-MI or target vessel 
revascularization) at 30 days, 9 months and one year was 5.8%, 8.2% and 9.8% 
respectively. Mortality was low, 1.5% after 30 days, 2.3% after 9 months and 3.1% 
after one year. There was no difference in any clinical outcome at any follow-up 
period between the two treatment groups. Particularly TVR was comparable in the 
two groups. Also the incidence of stent thrombosis was not different between the two 
groups during different follow-up periods.
Follow-up angiography was completed in 272 of 397 patients (69%), after 324 (SD 
88) days in the SES group and after 317 (SD 92) days in the PES group. Follow-up 
angiography was more often performed in males (58% no angiography, 78% 
angiography) and in younger patients. The mean (SD) in-stent late loss was 0.01 
(0.42) mm in the SES group vs 0.21 (0.50) mm in the PES group (difference, -0.20 
mm; 95% CI, P .001). The mean diameter stenosis at the follow-up angiography was 
higher in the PES group (table 4). However, no difference was observed in restenosis 
and TVR between the 2 groups.
DISCUSSION
In this randomized trial of SES versus PES in STEMI patients, we demonstrated a 
lower late loss after use of SES as compared to PES. However, there were no 
significant differences between the two stents regarding the incidence of MACE 
during follow-up, with similar low occurrence of stent thrombosis.
Several prospective randomized trials in primary PCI for STEMI and meta-analyzes 
(7, 9, 10) have shown the superiority of drug eluting stents as compared to bare 
metal stents in terms of TVR, with similar rates of death, reinfarction, and stent 
thrombosis. There were also several studies published comparing SES with PES in 
elective patients (11). SIRTAX compared SES with PES in 1012 patients undergoing 
PCI, and included both stable and unstable patients (12). The primary end point of 
that study was a composite of MACE (death from cardiac causes, myocardial 
infarction, and ischemia-driven revascularization of the target lesion) by nine months.
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Follow-up angiography was completed in 53 percent. A total of 227 patients with 
STEMI were included, but it is unclear whether these were treated with primary PCI. 
They found fewer MACE after SES, primarily by decreasing the rates of clinical and 
angiographic restenosis. The ISAR-DESIRE study randomizing 300 patients with 
angiographically significant in-stent restenosis to SES, PES, or balloon angioplasty 
found that both SES and PES were better than balloon angioplasty, and that SES 
was superior to PES (13). Other randomized studies comparing SES with PES were 
Reality, Sort Out II and Spirit III (14-16).
Few data have been reported so far on the comparison between these 2 stents in 
primary PCI. The PROSIT trial randomized 308 STEMI patients to SES and PES 
(17). Primary end point was MACE including death, reinfarction, stent thrombosis, 
and target lesion revascularization at 12 months. This study found no differences 
between the two stents. However, it must be remarked that angiographic follow-up 
was performed relatively early (6 months) in this study and this might have 
contributed to underestimate the benefits with SES in terms of late loss. Furthermore, 
the study was underpowered to show potential differences in the primary end point. 
Use of SES and PES in patients with STEMI was also compared in the RESEARCH 
and T-SEARCH Registries (18). In this relatively small consecutive patient cohort, 
without routine follow-up angiography, the incidence of MACE, and particularly TVR 
was comparable between sirolimus and paclitaxel eluting stents.
In our study, the largest trial so far conducted in primary PCI for STEMI, SES was 
associated with a significant reduction in late loss as compared to PES. However, 
these beneficial effects did not translate into clinical benefits, with a similar low 
incidence of stent thrombosis.
The differences of late loss between the sirolimus and paclitaxel stent may be caused 
by several mechanisms, including the stent itself and the eluting drug. Although both 
sirolimus and paclitaxel inhibit cell proliferation and other cellular processes, the 
working mechanism is different. An in-vitro study suggested that sirolimus reduces 
neointimal hyperplasia through a cytostatic mechanism while paclitaxel produces 
apoptotic cell death (19). A study in diabetic patients using intravascular ultrasound 
suggested that sirolimus inhibits neointimal hyperplasia more effectively (20).
Our sample size was too small to perform subgroup analyses. Furthermore, our trial 
was underpowered to detect differences in the incidence of clinical events during a 
relatively short (1-year) follow-up. Another limitation is that we had only follow-up
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angiography in 69% of patients. We had also no information on medical treatment 
during follow-up, in particular not on changes of the use and dosage of statin therapy. 
Moreover, it was a single centre trial, with the primary PCI performed by an 
experienced team.
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Table 1 -  Baseline characteristics
Variable Total
(N=397)
Rapamycin eluting
stent
(N=196)
Paclitaxel 
eluting stent 
(N=201)
Age (years) 61 ± 11 61 ± 12 61 ± 11
Men 72% 69% 74%
Current smoker 50% 50% 55%
Anterior wall infarct location 43% 44% 41%
Diabetes mellitus 8.6% 10.7% 6.5%
Previous Hypertension 30% 27% 33%
Previous 19% 19% 19%
Hypercholesterolem ia
Previous Myocardial Infarction 6.0% 6.1% 6.0%
Previous Percutaneous 6.3% 6.6% 6.0%
Coronary Intervention
Previous Coronary Bypass 1.3% 1.0% 1.5%
Surgery
Previous stroke 2.5% 2.0% 3.0%
Systolic blood pressure on 132 ± 23 132 ± 24 133 ± 24
admission (mm Hg)
Diastolic blood pressure on 80 ± 16 79 ± 15 80 ± 16
admission (mm Hg)
Heart rate on admission 74 ± 16 73 ± 15 74 ± 16
(beats/min)
Heart Failure on admission, 1.0% 0.5% 1.5%
Killip III or IV
TIMI risk score > 3 26% 27% 25%
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Table 2 - Baseline angiographic characteristics
Variable Rapamycin eluting Paclitaxel eluting P
stent stent value
(N=196) (N=201)
Multi vessel coronary disease 0.15
(%) 38% 31%
Target lesion coronary artery
Left Anterior Descending 0.53
Artery 44% 41%
Left Circumflex Artery 14.8% 16.9% 0.56
Right Coronary Artery 41% 42% 0.84
Thrombus Aspiration before 1.0% 1.5% 1.0
PCI
PCI immediately after 99% 99% 1.0
angiography
Stent not placed 1% 1.5% 0.62
Direct stenting 32% 35% 0.46
> 1 stent 13% 21% 0.04
Pre-dilatation balloon size 2.90 ± 0.42 2.85 ± 0.37 0.39
(mm)
Highest pressure (mm Hg) 11.79 ± 3.61 11.42 ± 3.15 0.58
Stent diameter (mm) 3.20 ± 0.33 3.19 ± 0.36 0.22
Total stent length (mm) 22.66 ± 8.82 23.81 ± 10.18 0.43
Use of additional devices 6% 6% 0.80
Use of Glycoprotein IIb/IIIa 28% 33% 0.23
inhibitors
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Table 3 - Clinical Outcomes up to 1 year after randomization
Variable Rapamycin coated
stent
(N=196)
Paclitaxel coated
stent
(N=201)
P value
Events until 30 days
Death 1.5% 1.5% 1.00
Re-MI 1.5% 1.5% 1.00
Target vessel 4.1% 4.0% 0.96
revascularization
Major Adverse Clinical Event* 5.6% 6.0% 0.88
(Sub) acute stent thrombosis 2.1% 2.0% 1.00
Events until 9 months
Death 2.6% 2.0% 0.75
Re-MI 3.1% 2.6% 0.74
Major Adverse Clinical Event* 8.3% 8.2% 0.96
Late stent thrombosis 1.1% 0.5% 0.62
Events until 1 year
Death 3.6% 2.6% 0.54
Re-MI 3.1% 3.1% 0.98
Target vessel 5.7% 6.7% 0.70
revascularization (%)
Major Adverse Clinical Event* 9.9% 9.7% 0.96
* Major Adverse Clinical Event (MACE) included death, re-MI or target vessel 
revascularization
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Table 4 - Results of quantitative coronary angiography at follow-up
Variable Rapamycin coated Paclitaxel coated P
stent (N=133) stent (N=139) value
Minimal Lumen Diameter at
follow-up (mm)
Mean ± SD 2.42 ± 0.53 2.26 ± 0.62 0.038
Median (Q1-Q3) 2.4 (2.16-2.77) 2.32 (1.90-2.72)
Diameter stenosis at follow-up
(%)
Mean ± SD 9.58 ± 17.7 16.68 ± 19.45 0.001
Median (Q1-Q3) 8.0 (-0.5-18.5) 13 (6-23)
Late loss (mm)
Mean ± SD 0.01 ± 0.42 0.21 ± 0.50 0.001
Median (Q1-Q3) -0.04 (-0.25 -  0.19) 0.12 (-0.12 -  0.44) 0.001
Restenosis > 50% 3.0% 4.3% 0.75
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CHAPTER 6
Efficacy and safety of Rapamycin as compared to 
Paclitaxel-eluting stents: a meta-analysis
Rapamycin vs Paclitaxel-eluting stents in STEMI
J Invasive Cardiol 2010 Jul;22(7):312-6.
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Abstract
Objectives: To compare the efficacy of Rapamycin eluting stents (RES) and 
paclitaxel eluting stents (PES) in patients undergo percutaneous coronary 
intervention.
Background: RES and PES differ importantly with respect to polymer coating and 
antiproliferative drugs. It is not yet clear whether there are any differences between 
RES and PES with regard to clinical outcome.
Methods: Systematic searches were conducted of randomised controlled trials 
(RCTs) comparing RES with PES in MEDLINE and the Cochrane Database of 
systematic reviews. A meta-analysis was done of all available randomised studies 
comparing PES with RES. Information on study design, inclusion and exclusion 
criteria, number of patients, and clinical outcome was extracted by two investigators. 
Disagreements were resolved by consensus. The primary outcome was re­
intervention, target lesion revascularisation (TLR) and target vessel revascularization 
(TVR). Stent re-stenosis, myocardial infarction (MI) and all cause mortality were 
secondary end points.
Results: Twenty one RCTs of RES versus PES with a total number of 10,147 patients 
were included in this meta-analysis. Indication for angioplasty was either acute 
coronary syndrome or stable angina. Mean follow-up period ranged from 6 to 24 
months. Rates of TLR were 4.9% vs. 7.0%; p=0.0009 and rates of TVR were 5.1 vs. 
8.3%; p<0.001 for RES vs. PES, respectively. The incidence of stent re-stenosis was 
3.9% for RES vs. 5.3% for PES; p=0.004. Rates of MI and all cause mortality were 
comparable.
Conclusions: This meta-analysis demonstrates that, as compared to PES, RES 
seems to be associated with a lower risk of re-intervention and stent re-stenosis. The 
risk of myocardial infarction and all cause death were similar between the 2 stents.
Key Words: Angioplasty • Drug-eluting stents • Re-intervention, Stent re-stenosis.
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Introduction
In patients with percutaneous coronary intervention (PCI), compared to balloon 
angioplasty and bare metal stenting, use of drug-eluting stents are associated with 
less restenosis and less need for recurrent revascularisation. There is, however, 
uncertainty about the most effective and safety between the two currently approved 
and most used drug-eluting stents i.e. Rapamycin-eluting stents (RES, Cypher, 
Cordis), and paclitaxel-eluting stents (PES, Taxus, Boston Scientific).
RES and PES differ importantly with respect to polymer coating and antiproliferative 
drugs [1]. A number of large randomised studies have demonstrated that both 
rapamycin- and paclitaxel-eluting stents significantly decrease restenosis rates in a 
variety of lesion types [2-17]. A recent meta-analysis of 16 randomised trials [1] 
showed that RES, compared to PES, significantly reduced the risk of reintervention 
and stent thrombosis and a trend toward a lower risk of MI without affecting mortality. 
However, since then several new randomised trials are conducted, presented and 
published, and their results were not included in that meta-analyses. The purpose of 
the present study was to compare both stents in a large series of patients with 
coronary artery lesions at high risk for restenosis.
Methods 
Literature review
We obtained results from all randomised trials on RES (Cypher, Cordis, Johnson & 
Johnson, Miami Lakes, Florida) and PES (TAXUS, Boston Scientific Corp,
Natick, Massachusetts). The literature was scanned by formal searches of electronic 
databases (MEDLINE, CENTRAL, EMBASE, and The Cochrane Central Register of
Controlled trials, http://www.mrw.interscience.wiley.com/cochrane), to October 2008, 
the scientific session abstracts in Circulation, Journal of College of Cardiology, 
European Heart Journal and American Journal of Cardiology from January 1990 to 
October 2008. Furthermore, oral presentations and/or expert slide presentations 
were included, searched on the transcatheter coronary therapeutics (TCT, 
www.tctmd.com), EuroPCR (www.europcr.com), ACC (American College of 
Cardiology; www.acc.org), AHA (American Heart Association; www.aha.org), and 
ESC (European Society of Cardiology; www.escardio.org) websites to October 2008.
94
The websites http://clinicaltrials. gov. and www.tctmd.com were also assessed in an 
attempt to locate unpublished studies. Information on study design, inclusion and 
exclusion criteria, number of patients, and clinical outcome was extracted by two 
investigators. Disagreements were resolved by consensus. In case of incomplete or 
unclear data, authors, where possible, were contacted. Finally, all co-authors had full 
access to all of the data in the study and take responsibility for the integrity of the 
data and the accuracy of the data analysis.
Endpoints/data abstraction
The primary clinical endpoint was re-intervention; target lesion revascularization 
(defined as re-intervention for stenosis within the stent or its 5-mm borders), target 
vessel revascularization(defined as re-intervention driven by a lesion in the same 
epicardial vessel as initially treated). Secondary endpoints were, stent re-stenosis, 
myocardial infarction all cause death.
Statistical analysis
For clinical outcomes, we used the intention-to-treat analysis, so that the 
denominator of the incidence was the total number of patients randomised to a given 
therapy. There were generally fewer patients available for the determination of 
several outcomes; therefore, to determine the incidence of these outcomes more 
accurately, we used the treatment-received (or protocol) analysis. Mantel-Haenszel 
model was used to construct random effects summary odds ratios (ORs) and risk 
differences. Potential publication bias was examined by constructing a ‘funnel plot’, in 
which sample size was plotted against ORs (for incidence of target lesion 
revascularisation, if available from a study).
Clinical data were initially analysed among all the studies. All outcomes were 
analysed at the maximal extent of clinical follow-up. All P-values were two-tailed, with 
statistical significance set at 0.05, and confidence intervals (CI) were calculated at 
the 95% level. All analyses were performed using SPSS 16.
Results
A total of 21 randomised trials including 10,147 patients were analysed (Table 1).
The indications for PCI included the whole clinical spectrum of coronary artery
95
disease. As shown in figures 1 -4, not every study mentioned all the outcomes that we 
planned to analyse. We performed analysis on available data.
TLR occurred in 189/3864 (4.9%) vs. 266/3812 (7.0%) in the RES and PES groups, 
respectively. Allocation to the RES group was associated with an OR of 0.66 (95% 
confidence interval (CI) 0.51 to 0.84, p =0.0009), (Fig. 1A). TVR occurred in 
147/2900 (5.1%) vs.237/2850 (8.3%) in the RES and PES groups, respectively. 
Allocation to the RES group was associated with an OR of 0.53 (95% CI 0.39-0.73, p 
<0.0001) for TVR (Fig. 1B). No potential publication bias was observed by analysis of 
the funnel plot (Fig 2).
Stent re-stenosis, occurred in 196/4993 patients in the RES group (3.9%) versus 
259/4918 patients in the PES group (5.3%). Allocation to the RES group was 
associated with an odds ratio (OR) for stent thrombosis of 0.68 (95% CI 0.52-0.88, p 
=0.004) (figure 3).
Myocardial infarction occurred in 168/4605 patients (3.6%)in the RES group versus 
194/4546 (4.3%) patients in the PES group. Allocation to the RES group was 
associated with an OR for MI of 0.84 (95% CI 0.68 to 1.04, p=0.12) (figure 4).
All cause mortality occurred in 110/4600 in RES group (2.4%) versus 115 patients in 
the PES group (2.5%). Allocation to the RES group was associated with an OR for all 
cause mortality of 0.94 (95% CI 0.72-1.24, p=0.68) (figure 5).
Discussion
In this meta-analysis we compared the clinical outcomes after implantation of 
rapamycin eluting stent (RES) versus paclitaxel eluting stent (PES) in a large patient 
population, representative of the whole clinical spectrum of coronary artery disease. 
Re-intervention was clinically driven in 3 studies[2,8,17] and two additional studies 
mentioned clinically as well as angiographic ally driven re-intervention [13,14]. In all 
the other studies re-intervention was angiographically driven.
RES, as compared to PES, was associated with a lower need for re-intervention, less 
often stent re-stenosis and a trend towards lower risk of myocardial infarction, without 
affecting the risk of all cause mortality. These results confirm a previous meta­
analysis of 16 randomised trials [1]. In the current Meta-Analysis, compared with the 
previous one, we add results of five additional more recent trials [18-22] and data of 
two trials that are recently fully published [16-17]. Furthermore, we analysed rates of 
TLR and TVR separately.
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Use of drug-eluting stents
Because the incidence of stent thrombosis may be higher in patients with drug eluting 
stents than in bare metal stents, and also the incidence of stent thrombosis may be 
higher in patients undergo PCI [23], there have been concerns about using 
drug eluting stents. However, various registries, randomised trials, and recent meta­
analyses on patients undergoing primary PCI have demonstrated that use of DES is 
safe and is associated with significantly reduced rates of restenosis and repeat 
intervention without an increased risk of myocardial infarction or stent thrombosis at 
intermediate-term follow-up [24-26]. Additional large trials with hard clinical end 
points and longer follow-up are needed before routine DES use can be 
recommended in more patients undergoing primary PCI.
Mechanisms
Delayed healing characterized by persistent fibrin deposition, poorer 
endothelialization, and local hypersensitivity reaction may explain the late occurrence 
of thrombosis-related events with drug eluting stents [27]. Previous reports showed 
that these phenomena are more pronounced with PES than RES [28].
Although both sirolimus and paclitaxel inhibit cell proliferation and other cellular 
processes, the working mechanism is different. Sirolimus induces G1 cell cycle 
inhibition, and paclitaxel mainly induces M-phase arrest. An in-vitro study suggested 
that sirolimus reduces neointimal hyperplasia through a cytostatic mechanism while 
paclitaxel produces apoptotic cell death [29]. A study in diabetic patients using 
intravascular ultrasound suggested that sirolimus inhibits neointimal hyperplasia 
more effectively [30]. Three studies compared RES with PES in patients with 
diabetes showed that in these patients RES are more effective[4,19,20].
Furthermore, differences in the early systemic inflammatory response after PCI may 
partially explain the differences in clinical outcome after RES and PES implantation.
A recent study showed that implantation of both types of DES induce an 
acute inflammatory response, as assessed by CRP and IL-6 plasma concentrations, 
where RES implantation resulted in lower inflammatory responses compared with 
PES implantation. This may be of clinical relevance since this difference was 
associated with the degree of re-stenosis at 8-months follow-up [31].
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In addition, another 'olimus (everolimus) eluting stent shown to be superior to PES. 
The SPIRIT III trial demonstrated a significant reduction in the in-segment late loss 
with everolimus eluting stent (EES) compared with PES. at 8 months and non­
inferiority to PES for the clinical endpoint of target vessel failure at 1 year and 
resulted in a significant reduction in major adverse cardiac event [32,33]. The Spirit 
IV trial, that presented during the 2009 annual Transcatheter Cardiovascular 
Therapeutics (TCT), showed a 2.6% absolute difference in the rate of target lesion 
failure between the two stents, statistically favoring the EES [34]. Furthermore, the 
COMPARE trial [35] showd that use of EES vs. PES in real worl patients was 
associated with 31 relative risk reduction (RR) in the composite of safety and efficacy 
(all-cause mortality, myocardial infarction, and TVR) within 12 months. The difference 
was driven by lower rate, of: early stent thrombosis, 0.7 vs. 2.5% (RRR 74%); fewer 
myocardial infarctions, 2.8% versus 5.3%;and fewer target-lesion revascularisations, 
2.3% versus 6.0%. Based on our meta-analysis and the above mentioned studies, 
RES might be preferred above PES.
Limitations
This meta-analysis was not performed on individual patient data, caution should be 
exercised in the interpretation of the results, given the potential clinical heterogeneity 
among trials, due to varying patient population, and varying definition of variables.
The results of our meta-analysis may only be applied for patients fulfil the criteria of 
these studies and may not be applied for registries. Furthermore, the meta-analysis is 
limited by the design of the original studies, with particularly the short follow-up period 
of several studies.
Conclusions
This meta-analyses show that use of RES, as compared to PES, is associated with a 
significantly lower need for re-intervention and less often stent occlusion, without 
affecting the risk of myocardial infarction or all cause mortality.
98
1- Schömig A, Dibra A, Windecker S, et al. A meta-analysis of 1B randomized 
trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with 
coronary artery disease. J Am Coll Cardiol 2007;50:1373-1380.
2- Goy JJ, Stauffer JC, Siegenthaler M, et al. A prospective randomized 
comparison between paclitaxel and sirolimus stents in the real world of 
interventional cardiology: the TAXI trial. J Am Coll Cardiol 2005;45:308-311.
3- Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or 
paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in 
patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 
2005;293:165-171.
4- Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus eluting stents 
to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-670.
5- de Lezo J, Medina A, Pan M, et al. Drug-eluting stents for complex lesions: 
randomized rapamycin versus paclitaxel CORPAL study (abstr). J Am Coll 
Cardiol 2005;45:75A.
6- Di Lorenzo E, Varricchio A, Lanzillo T, et al. Paclitaxel and sirolimus stent 
implantation in patients with acute myocardial infarction (abstr). Circulation 
2005;112:U538.
7- Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel- 
eluting stents for coronary revascularization. N Engl J Med 2005;353:653-662.
8- Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost- 
effectiveness of drug-eluting stents compared with a third generation bare- 
metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats 
Trial (BASKET). Lancet 2005;366:921-929.
References
99
9- Cervinka P, Costa MA, Angiolillo DJ, et al. Head-to-head comparison between 
sirolimus-eluting and paclitaxel-eluting stents in patients with complex 
coronary artery disease: an intravascular ultrasound study. Catheter 
Cardiovasc Interv 2006;67:846-851.
10- Han YL, Wang XZ, Jing QM, et al. Comparison of rapamycin and paclitaxel 
eluting stent in patients with multi-vessel coronary disease (in Chinese). 
Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:123-126.
11- Mehilli J, Dibra A, Kastrati A, et al. Randomized trial of paclitaxel- and 
sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006;27:260- 
266.
12-Kim YH, Park SW, Lee SW, et al. Sirolimus-eluting stent versus paclitaxel- 
eluting stent for patients with long coronary artery disease. Circulation 
2006;114:2148-2153.
13- Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxel eluting stents 
in de novo coronary artery lesions: the REALITY trial: a randomized controlled 
trial. JAMA 2006;295:895-904.
14-Zhang Q, Zhang RY, Zhang JS, et al. One-year clinical outcomes of Chinese 
sirolimus-eluting stent in the treatment of unselected patients with coronary 
artery disease. Chin Med J (Engl) 2006; 119:165-168.
15- Petronio AS, De Carlo M, Branchitta G, et al. Randomized comparison of 
sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior 
descending artery: an intravascular ultrasound study. J Am Coll Cardiol 
2007;49:539-546.
100
16-Prospective Randomized Comparison of Sirolimus- Versus Paclitaxel-Eluting 
Stents for the Treatment of Acute ST-Elevation Myocardial Infarction: PROSIT 
Trial. Catheter Cardiovasc Interv 2008;72:25-32.
17-Gall0e AM, Thuesen L, Kelbæk H, et al. Comparison of Paclitaxel- and 
Sirolimus-eluting stents in everyday clinical practice. The SORT OUT II 
Randomized Trial. JAMA 2008;299:409-416.
18-Wessely R, Kastrati A, Mehilli J, et al. Randomized trial of rapamycin- and 
paclitaxel-eluting stents with identical biodegradable polymeric coating and 
design. Eur Heart J 2007;22:2720-2725.
19- Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus- 
versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. J 
Am Coll Cardiol 2008 ;52:727-733.
20-Kim MH, Hong SJ, Cha KS, et al. Effect of Paclitaxel-eluting versus sirolimus- 
eluting stents on coronary restenosis in Korean diabetic patients. J Interv 
Cardiol 2008;21:225-231.
21- Mehilli J, Kastrati A, Byrne RA, et al; LEFT-MAIN Intracoronary Stenting and 
Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main 
Lesions Study Investigators. Paclitaxel- versus sirolimus-eluting stents for 
unprotected left main coronary artery disease. J Am Coll Cardiol 
2009;53:1760-1768.
22-Juwana YB, Suryapranata H, Ottervanger JP, et al. Comparison of Rapamycin 
and Paclitaxel eluting stents in patients undergoing primary percutaneous 
coronary intervention for ST elevation myocardial infarction. Am J Cardiol 
2009:104;205-209.
101
23- de la Torre-Hernández JM, Alfonso F, Hernández F, et al. Drug-eluting stent 
thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio 
ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 
2008;51:986-990.
24-Melfi R, Nusca A, Patti G, Di Sciascio G. The risks and benefits of drug-eluting 
stents in the setting of STEMI. Curr Cardiol Rep 2008;10:402-406.
25-Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on 
drug-eluting stents vs. bare-metal stents in patients with acute myocardial 
infarction. Eur Heart J 2007;28:2706-2713.
26-De Luca G, Stone GW, Suryapranata H, et al. Efficacy and safety of drug- 
eluting stents in ST-segment elevation myocardial infarction: a meta-analysis 
of randomized trials. Int J Cardiol 2009;133:213-222.
27-Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: 
delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
28- Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed 
healing and persistent inflammation at sites of overlapping sirolimus- or 
paclitaxel-eluting stents. Circulation 2005;112:270-278.
29-Parry TJ, Brosius R, Thyagarajan R, et al. Drug-eluting stents: sirolimus and 
paclitaxel differentially affect cultured cells and injured arteries. Eur J 
Pharmacol 2005;524:19-29.
30-Jensen LO, Maeng M, Thayssen P, et al. Neointimal hyperplasia after 
sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: 
The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular 
Ultrasound Trial. Eur Heart J 2008;29:2733-2741.
102
31-Li JJ, Yan HB, Xiang XP, et al. Comparison of changes in early inflammatory 
markers between sirolimus-and paclitaxel-eluting stent implantation. 
Cardiovasc Drugs Ther 2009;23:137-143.
32-Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, W illiams J, Farhat N, 
Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ.
Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in 
patients with coronary artery disease: a randomized trial. JAMA 2008; 
299:1903-1913.
33-Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, William J, Farhat N, 
Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip 
DE, Petersen JL, investigators tSI. Randomized comparison of everolimus- 
eluting and paclitaxel-eluting stents: two-year clinical follow-up from the 
SPIRIT III Trial. Circulation 2009;119:680-686.
34-Stone G.SPIRIT IV: A Prospective Randomized Trial of Everolimus-Eluting vs. 
Paclitaxel-Eluting Stents available at http://www.tctmd.com.
35-Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, 
Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents 
in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.
103
Figure legend:
Figure 1 A: Target lesion revascularisation 
Figure 1B: Target vessel revascularisation
Figure 2: Funnel plot of the studies included in the meta-analysis. Sample size of 
each study was plotted against the odds ratio for target lesion revascularization. No 
skewed distribution was observed, suggesting no publication bias
Figure 3: Stent re-stenosis during follow-up
Figure 4: Myocardial Infarction during follow-up
Figure 5: All cause mortality during follow-up
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Table 1: General characteristics of the trials
Study Publication
year
No. of 
patients
Mean age 
(yrs)
Patient profile Primary end point Mandated follow-up 
angiography
Mean length of fo llow - 
up (months)
TAXI [2] 2005 202 64 Unselected Death, MI, reintervention no 7
ISAR-DESIRE [3] 2005 200 64 In-stent restenosis Angiographic restenosis yes 12
ISAR-DIABETES [4] 2005 250 68 Diabetic Angiographic late loss yes 9
CO RPAL [5] 2005 515 61 Unselected Angiographic restenosis and clinical outcome yes 6
Di Lorenzo et al [6] 2005 120 64 Acute MI Death, MI, reintervention no 6
SIRTAX [7] 2005 1,012 62 Unselected Death, MI, reintervention yes 9
Basket [8] 2005 545 64 Unselected patients Cost-effectiveness based on the com posite of death, MI or reintervention no 6
Cervinka e t al [9] 2006 70 56 Complex lesion and patients Neointimal volum e in intravascular ultrasound assessm ent yes 6
Han at al [10] 2006 416 NA Multivessel disease Death, MI, reintervention no 20
ISAR-SMART [11] 2006 360 67 Small vessel, non diabetic Angiographic late loss yes 12
LONG DES II [12] 2006 500 61 Long lesions Angiographic restenosis yes 9
REALITY [13] 2006 1,353 63 Relatively unselected patients Angiographic restenosis yes 12
Zhang e t al [14] 2006 449 64 Unselected patients Death, MI, reintervention no 12
Petronio e al [15] 2007 85 63 Complex lesion Neointimal area in intravascular ultrasound assessm ent yes 9
PROSIT [16] 2008 308 62 Acute MI Cardiac death, reinfarction, stent throm bosis or target lesion revascularization yes 12
SORT OUT II 17 2008 2,098 64 Unselected patients Death, mi or reintervention no 9
W essely, et al [18] 2008 91 67 Stable or unstable angina In-stent late lumen loss yes 9
Lee S W  et al [19] 2008 400 61 Diabetic In segm ent restenosis yes 9
Kim MH et al [20] 2008 169 62 Diabetic Angiographic and clinical outcome yes 6
ISAR LM 21 2008 607 69 Sym ptom atic left main disease Death, MI, or repeat revascularization yes 24
CEZAR 22 2009 397 61 AMI Late lumen loss yes 12
Figure 1A : Target lesion revascularisation
Study or Subgroup
RE PE
EventsTotal Event Total Weigh
Odds 
M-H, Ran dom, 95%
Odds Ratio 
M-H, Random, 95%
Cervinka et al 1 3 1 3 0.8 1.00 [0.06,
CORPAL 1 26 1 275 8.3 0.63 [0.30,
ISAR LM 2009 2 30 28 40 13.5 1.15 [ 0.67,
ISAR-DIABETES 8 12 18 12 6 . 3 0.50 [0.20,
Kim MH et al 2 9 54 59 28.0 0.43 [0.09,
2oe SW 4 20 1 250 48.3 0.24 [0.08,
2ONG-DES II 6 25 15 25 58.8 0.72 [0.12,
Petro nio et al 1 04 81 04 08.8 1.02 [0 .06,
PROSIT 2008 4 15 1 15 38.9 0.38 [0.12,
REALITY 4 68 40 46 186.6 1.95 [0.62,
SIRTAX 21 50 41 90 84 . 0 1.56 [0.33,
SORT-OUT II 4 10 6 62 10 3 19 . 2 0.95 [0.51,
TAXI 2005 82 51 0 11 31 0 81 .0 1.98 [0 .18,
Wessely et al 2008 4 24 1 04 38.6 0.29 [0.09,
Total (95% 3864 3812 100.0 0.66 [0.51, 0.84]
Tot al 18 26
Hetntogeneity: Tau2 = 0.04 ; <3hi2 = 16.72 , df = 13 (P = 0.21);
12 = 0 
Test for overall effect: Z = 3.31 (P = F
1 1 
PES
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Figure 1B: Target vessel revascularisation
RE PE Odds Ratio Odds Ratio
Study or SubgroupEventsTotal EventsT otal Weight
Basket 2005 8 264 1 281 9.0
Cervinka et al 2006 1 3 72 3 1.5
Cezar 2009 4 19 6 2 230 1 6.3
Di Lorenzo 2005 0 6 01 6 0.9
Han et al 2006 9 201 0 1 20 6 6.3
Isar Smart 3 13 198 31 204 11.9%
Isar-Desire 2005 8 100 10 100 8.7
KIm MH 2008 8 9 96 9 0.2
Lee SW 2008 4 250 0 1 250 0 0.0
Long-Desll 8 250 15 250 0.1
Sort-Out II2008 70 1065 89 1033 21.2%
Zhang at el 2006 14 225 1 187 10.7%
Total (95% CI) 2900 2850 100.0%
Total events 147 237
Heterogeneity: Tau2 = 0.09; Chi2 =^ 16.67,, df = 11 (P = C
Test for overall effect: Z = 3.96 (P < 0.0001)
M-H, Random, 95% CI_ M-H, Random, 95% CI
0.49 [0.21, 1.14]
0.43 [0.04, 4.98] -------- "--------
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Figure 2: Funnel plot of the studies included in the meta-analysis. Sample size of each study was plotted against 
the odds ratio for target lesion revascularization. No skewed distribution was observed, suggesting no publication bias
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Figure 3: Stent re-stenosis during follow-up
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Figure 4: Myocardial Infarction during follow-up
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Figure 5: All cause mortality during follow-up
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CHAPTER 7
Routine Use of a new endothelial progenitor cells antibody-coated 
stent in patients undergoing primary PCI for ST-segment elevation 
Myocardial infarction: A prospective registry in all-comers
Submitted for publication
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ABSTRACT
Aims - To assess the safety of routine use of a new endothelial progenitor cells 
antibody-coated stent in patients with primary PCI for ST elevation Myocardial 
Infarction (STEMI).
Background - Although endothelial progenitor cell (EPC) capture stents may be safe 
and may potentially prevent stent thrombosis and restenosis, there are only limited 
data on it’s use in primary PCI.
Methods - Data on consecutive patients with STEMI treated with the endothelial 
progenitor cells antibody-coated stent (Genous Bio-Engineered R Stent) were 
collected in a prospective registry. Clinical follow-up was performed at 30-days and at 
1-year. MACE was defined as the combined end point of death, recurrent MI, stent 
thrombosis or additional revascularisation by either PCI or CABG.
Results -  From January to September 2008, a total of 430 consecutive STEMI 
patients were included in the registry. Of these, 9% had diabetes and 35% had 
anterior infarction. At angiography, 55% of the patients had TIMI 0 flow before PCI. 
More than one stent was necessary in 20.2% of patients. TIMI 3 flow was achieved in 
94% of patients. Acute stent thrombosis occurred in 1.2%. The incidence of events 
after one year follow-up was low, with a total mortality of 3.7% and the incidence of 
late stent thrombosis 0.8%. Predictors of MACE up to one year were higher age, not­
smoking, small stent diameter, no TIMI 3 flow after PCI and use of an intra-aortic 
balloon pump.
Conclusions -  Use of the endothelial progenitor cells antibody-coated Genous stent 
is safe and associated with a low event rate. Longer follow-up studies are necessary 
to confirm its long-term efficacy.
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INTRODUCTION
Although the use of stents in general is safe during percutaneous coronary 
intervention (PCI), concerns remain with regard to safety of stenting in patients 
with ST-elevation Myocardial Infarction (STEMI), particularly because of an 
increased risk of stent thrombosis . This may be related to the fact that healing is 
impaired after stenting of a ruptured plaque, leaving uncovered stent struts as 
substrate for thrombosis.
To address this issue, a new type of stent has been developed (Genous stent), 
which is coated with murine monoclonal antihuman CD34 antibodies designed to 
attract circulating endothelial progenitor cells (EPC). EPCs are bone-marrow 
derived cells that are present in circulating blood, and have the ability to 
differentiate into mature endothelial cells, which may potentially accelerate the 
healing process, protect against thrombus, and minimize re-stenosis. There have 
been several published studies on the clinical use of EPC capturing stents (1-5).
A small study in 16 patients demonstrated a nine-month composite major adverse 
cardiac and cerebrovascular events of 6.3% as a result of a symptom-driven 
target vessel revascularization in a single patient (1). In this study, at six-month 
follow-up, mean angiographic late luminal loss was 0.63 mm, and percent stent 
volume obstruction by intravascular ultrasound analysis was 27 %. In a cohort of 
80 consecutive patients with high-risk angiographic and/or clinical features, it was 
shown that the EPC capturing stent is safe and effective, with satisfactory 
immediate results and mid-term outcome, without evidence of stent thrombosis 
(2).
Although EPC capture stent may be in theory safe and even may prevent stent 
thrombosis and restenosis, there are only limited data on its use in primary PCI 
for STEMI. Most published studies have a very small sample size (3, 4). We 
report the results of a prospective study of all comers with STEMI who were 
treated with a Genous stent.
METHODS
Population and procedures
From January to September 2008, individual patient data from all patients with 
admission diagnosis of STEMI treated with primary PCI and the endothelial
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progenitor cell capture stent (Genous Bio-Engineered R Stent) at the Isala 
klinieken (Zwolle, the Netherlands) were prospectively recorded in a registry. To 
avoid double inclusion of patients, only the first recorded admission for STEMI 
during the study period was used. Patients were diagnosed with STEMI if they 
had chest pain of > 30 minutes duration and ECG changes with ST segment 
elevation > 2 mm in at least 2 precordials and > 1 mm in the limb leads. Before 
the primary PCI procedure all patients received 300 mg of aspirin and 5.000 IU 
heparin intravenously. In addition to aspirin and heparin, clopidogrel 600 mg was 
given orally, and continued with 75 mg daily during one year. Primary PCI was 
performed with standard techniques if the coronary anatomy was suitable for 
angioplasty, and if possible a Genous stent was placed. The Genous stent 
comprises a covalently coupled polysaccharide matrix coating with monoclonal 
murine anti-human CD34+ antibodies on the adluminal stent surface, attached to 
a 316L stainless steel stent (Genous Bio-engineered R stent™, OrbusNeich 
Medical Technologies, Fort Lauderdale, FL, USA). The Genous stent received CE 
mark on 11 August 2005. PCI success was determined by the classification 
system of the Thrombolysis in Myocardial Infarction (TIMI) trial, in which a grade 3 
blood flow indicates normal flow within the vessel, in combination with a 
myocardial blush grade 2 or 3. Additional treatment with glycoprotein IIb/IIIa 
inhibitors or stents was left to the discretion of the treating cardiologist. All 
patients were treated with optimised drug-therapy including angiotensin­
converting enzyme inhibitors, p-blockers and lipid-lowering drugs where 
appropriate.
Measurements (definitions, end points)
Reinfarction was defined by the presence of recurrent ischemic symptoms or 
electrocardiographic changes accompanied by a creatine kinase level that was 
more than twice the upper limit of the normal range (with an elevated MB isoform 
level) or more than 50 percent higher than the previous value obtained during 
hospitalization with or without stent thrombosis or development of Q waves. Stent 
thrombosis was defined as acute ischemic symptoms (typical chest pain with 
duration more than 20 min) accompanied by occlusion of the infarct related 
vessel, originating in the peri-stent region. Acute stent thrombosis was defined as 
the occurrence of stent thrombosis within 24 hours after stent implantation,
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subacute stent thrombosis as the occurrence of stent thrombosis more than 24 
hours but less than 30 days after stent implantation and late stent thrombosis if 
stent thrombosis was observed after 30 days. Major bleeding was defined as 
either intracranial bleeding or overt bleeding with a decrease in hemoglobin >5 
g/dl (> 3.1 mmol/L) or a decrease in hematocrit >15% within 48 hours after 
admission. Major adverse cardiac clinical events (MACE) at one year were 
defined as the combined end point of death, recurrent MI, PCI of the culprit lesion, 
urgent bypass surgery or stent trombosis
Data collection and follow-up
Follow-up information was obtained from the patient's general physician or by 
direct telephone interview with the patient up to 1 year after admission. Study 
approval was obtained from the medical ethics committee of our hospital and all 
patients gave written informed consent for the collection of data. MACE at one 
year was defined as the combined end point of death, recurrent MI or additional 
revascularisation by either PCI or CABG.
Statistical Analysis
Statistical analysis was performed with the Statistical Package for the Social 
Sciences (SPSS Inc., Chicago, IL, USA) version 15.0.1. Continuous data were 
expressed as mean ± standard deviation and categorical data as percentage, 
unless otherwise denoted. Differences between continuous data were performed 
by students t test and the chi-square or Fisher’s exact test were used as 
appropriate for dichotomous data. Multivariable logistic regression analysis was 
performed to test the independent association between baseline characteristics 
and MACE at on year. Significant variables analyzed are reported with their 
respective odd ratios and 95% confidence intervals. Kaplan-Meier method was 
used for survival rate. For all analyses, statistical significance was assumed when 
the two-tailed probability value was < 0.05.
RESULTS
During the study period, a total of 430 patients were included in this prospective 
registry. Mean age was 60 years, and 76.9% was male. General characteristics of
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the patients are summarized in Table 1. The majority of patients were 
hemodynamically stable on admission (89% Killip class 1).
Angiography
The findings of angiography are listed in table 2. The majority of patients had 
single vessel disease. The LAD was the most common infarct related vessel. On 
the initial angiography, TIMI 0 in the infarct related vessel was observed in 55% of 
the patients. Approximately 95% of the patients had TIMI 3 flow after PCI.
Follow-up
All patients had one-year follow-up. The incidence of acute stent thrombosis was 
1/.2%. The occurrence of events up to one year is listed in Table 3. The event 
rate was low, with total mortality at one year of 3.7%. The incidence of stent 
thrombosis at 1 year was 3.4%. Patients with stent thrombosis up to 1 year were 
older (66 years versus 61 years, p 0.20) and had more often a history of 
hypertension (64% vs 39%, p = 0.12). Stent diameter (3.2 mm without stent 
thrombosis vs 3.1 mm in those with stent thrombosis) was not different, but mean 
stent length was (not significant) longer (25.2 mm □ 8.9) in patients with stent 
thrombosis compared to those without stent thrombosis (23.6 mm □ 9.9, p = 0.6). 
Table 4 shows differences between patients with and without MACE as recorded 
up to one year follow-up. Independent predictors of MACE up to one year were 
higher age, not-smoking, small stent diameter, no TIMI 3 flow after PCI and use of 
an intra-aortic balloon pump.
DISCUSSION
This largest registry of STEMI patients treated with a Genous stent showed 
favorable mid-term results with a low incidence of events. Predictors of MACE up 
to one year were higher age, not-smoking, small stent diameter, no TIMI 3 flow 
after PCI and use of an intra-aortic balloon pump.
Mechanism of EPC capturing by the Genous stent
EPCs were isolated primarily in 1997 as CD34+ haematopoietic progenitors from 
peripheral Blood (6). EPCs share common properties and function, and they can 
proliferate and differentiate in vitro to mature endothelial cells. EPCs are
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mobilized from bone marrow into peripheral blood and recruited to the foci of 
pathophysiological neovascularization and reendothelialization, thereby 
contributing to vascular regeneration. Severe EPC dysfunction is an indicator of 
poor prognosis and severe endothelial dysfunction. The number of circulating and 
functional activities of EPCs is reduced in smokers (7) and the eldery (8). In a 
study with 120 individuals (43 control subjects, 44 patients with stable coronary 
artery disease, and 33 patients with acute coronary syndromes), reduced levels of 
circulating EPCs independently predicted atherosclerotic disease progression (9). 
Also in a larger study, with patients with coronary artery disease as confirmed on 
angiography, the level of circulating CD34+KDR+ endothelial progenitor cells 
predicted the occurrence of cardiovascular events and death from cardiovascular 
causes after 12 months (10).
Therefore, the aim of the EPC capture stent was to improve the formation of a 
confluent endothelial layer on the stent. In an in-vivo study, at 1 h after 
deployment of the EPC capture stent, more than 90% cell coverage was shown, 
while the bare stainless steel stents were still almost completely devoid of cells 
(11).
Stent thrombosis
Despite combined antiplatelet therapy, stent thrombosis persists at a rate of
0.5%-2% in elective interventions, and up to 6% in patients with acute coronary 
syndromes (12), and is associated with a worse prognosis (13). The incidence of 
stent thrombosis in our “all comers” population was relatively low, and 
comparable to the selected patients reported in randomized trials (14). However, 
the incidence of stent thrombosis in our analysis was higher than the report of Lee 
et al, who observed in 321 patients with primary PCI only one patient who 
developed acute stent thrombosis, another two with subacute stent thromboses, 
and no late thrombosis (15).
Several clinical and angiographic predictors of stent thrombosis have been 
identified, including a poor post-procedural result such as inadequate stent 
expansion, residual dissection, and inappropriate platelet aggregation inhibition 
(16, 17). Clopidogrel is the thienopyridine of choice for dual antiplatelet therapy 
after PCI, but the efficacy is limited because clopidogrel’s antiplatelet activity is 
delayed since the drug needs to be metabolized into its active form and there is
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strong variability in patient response to clopidogrel. To overcome shortcomings of 
clopidogrel, new more potent oral platelet aggregation inhibitors have been 
introduced as prasugrel and cangrelor. The TRITON-TIMI 38 (TRial to assess 
Improvement in Therapeutic Outcomes by optimizing platelet inhibition with 
prasugrel) found that in patients with acute coronary syndromes scheduled for 
PCI, prasugrel (60 mg loading dose and a 10 mg daily maintenance dose), 
compared with approved doses of clopidogrel (300 mg loading dose and a 75 mg 
daily maintenance dose), resulted in significantly reduced rates of ischemic 
events (18). Also a sub-analysis of this study of patients with primary PCI for 
STEMI showed after 15 months decreased myocardial infarction and stent 
thrombosis (19).
Further directions
There have been several published studies on the clinical use of EPC capturing 
stents (1-5). Although in a small study (n=11) by Kaul et al, a high rate of 
restenosis was observed, this should be confirmed in larger studies. A 
randomized trial in patients with lesions carrying a high risk of restenosis, showed 
that use of the Genous stent was associated with more repeat revascularizations 
as compared with the Taxus stent (20). In this study, however, there were four 
stent thromboses with Taxus stent, but none with the Genous stent. Theoretically, 
the enhanced endothelialization may also cause unwanted angiogenesis which 
may favour neoplasia progression and paradoxically atherosclerotic plaque 
expansion and complications in some patients. A balloon catheter coated with 
Paclitaxel has recently been developed to reduce restenosis, and have been used 
routinely to prevent in-stent restenosis (21, 22). Whether a combination of EPC 
capture stent and drug eluting balloon may be beneficial should further be 
explored.
Another subject to be explored is the use of EPC capture stents in patients with 
acute stent thrombosis. Acute stent thrombosis is associated with high morbidity 
and mortality, and the incidence of recurrent acute stent thrombosis is high in 
these patients (23). Whether EPC capture stents will decrease this risk in these 
patients should be assessed in randomised controlled clinical trials. Another 
opportunity for EPC capture stents consist of patients requiring surgical
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procedures early after coronary stent placement, since antiplatelet drug can 
possibly more safe discontinued after PCI using EPC capture stents (24).
Limitations and strengths
Our study had several limitations. It concerned a non-randomized registry with 
inclusion of patients in only one hospital with high experience with primary PCI. 
However, this is a real world registry of all-comers with STEMI, treated with a 
EPC capture stent. We did not perform routine control angiography after 6 or 9 
months, and no EPC count was obtained. However, this registry reflects daily 
practice and was not limited by exclusion criteria.
Conclusion
Use of the endothelial progenitor cells antibody-coated Genous stent in a large 
unselected cohort of STEMI patients was safe, and associated with a low event 
rate at mid-term follow up. Longer follow-up studies are necessary to confirm 
long-term efficacy.
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TABLE 1 -  General characteristics in 446 patients, treated with endothelial progenitor cells
antibody-coated stent for ST elevation Myocardial Infarction
% or mean ± SD
Age (years) 60 ± 12.4
Age > 75 years 17.5
Male gender 76.9
Current smoker 39.5
Anterior infarct location 35.2
Diabetes mellitus 9.4
Hypertension 35.0
Known hypercholesterolemia 16.3
Family history 31.9
Previous MI 4.4
Previous PCI 4.0
Previous CABG 0.9
Previous stroke 1.6
Systolic blood pressure on admission (mm Hg) 134 ± 25
Diastolic blood pressure on admission (mm Hg) 82 ± 16
Heart rate on admission (beats/min) 75 ± 17
Killip 1 on admission 88.8
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TABLE 2 - Angiographic characteristics in 430 patients with STEMI treated with endothelial
progenitor cells antibody-coated stent
% or mean ± SD
Vessel disease
Single vessel disease 58.9
Two vessel disease 30.2
Three vessel disease or Left Main 10.9
No collaterals 61.5
Target lesion coronary artery
LAD (%) 44.8
RCX (%) 14.9
RCA (%) 39.7
One stent placed (%) 79.8
Balloon size 2.9 ± 0.44
Highest pressure 12.7 ± 3.7
Stent diameter (mm) 3.18 ± 0.34
Total stent length (mm) 23.8 ± 9.6
Use of additional devices, as thrombosuction 22.6
Intra Aortic Balloon Pumping 6.7
TIMI 3 flow after PCI 94.2
Blush 3 after PCI 55.2
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Table 3 -  Events recorded during follow-up in 430 patients with STEMI treated with
endothelial progenitor cells antibody-coated stent
Events until 30 days %
death 2.8
recurrent myocardial infarction 0.9
additional pCi 7.2
coronary bypass surgery 2.1
(sub) acute stent thrombose 2.6
Acute 1.2
Subacute 1.4
Major bleeding 1.4
Bleeding 3.0
MACE* 6.5
Events until 1 year
death 3.7
re-MI 2.3
additional PCI 14.5
coronary bypass surgery 4.6
stent trombosis 3.4
Major bleeding 2.5
Bleeding 5.2
MACE* 12.3
* Combination of death, recurrent MI, PCI of culprit lesion, urgent bypass surgery or stent 
trombosis
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Table 4 -  Differences between patients with and without MACE* recorded up to one 
year in 430 patients with STEMI treated with endothelial progenitor cells antibody-
coated stent
Without MACE** 
N = 402
With MACE** 
N = 28
P value
% or mean ± SD % or mean ± SD
Age (years) 61.24 ± 12.69 67.91 ± 13.64 0.008
Age > 75 years 16.0 35.7 0.016
Male 77.1 71.4 0.491
Hypertension 36.9 55.6 0.053
Diabetes mellitus 10.7 7.4 1.000
Previous Myocardial Infarction 5.3 11.1 0.188
Previous CABG 1.2 0 1.000
Previous PCI 5.2 3/27 (11.1%) 0.185
Hypercholesterolaemia 19.0 18.5 0.946
Smoking 44.1 22.2 0.026
Positive family history 38.9 37.0 0.847
Killip class > 2 on admission 5.5 10.7 0.217
LAD the infarct related vessel 44.2 55.6 0.252
TIMI 0 before PCI 54.6 70.4 0.111
Multivessel disease 41.1 57.7 0.097
Direct stenting 37.0 22.2 0.122
Stent diameter (mm) 3.19 ± 0.33 3.03 ± 0.38 0.017
Stent length (mm) 23.56 ± 9.85 24.37 ± 10.01 0.678
Highest pressure (mm Hg) 12.49 ± 3.78 12.56 ± 3.79 0.926
TIMI < 3 after procedure 4.5 30.8 < 0.001
Intra Aortic Balloon Pumping 5.1 30.8 < 0.001
* Combination of death, recurrent MI, PCI of culprit lesion, urgent bypass surgery or stent
trombosis
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Summary
Background: The benefits of Primary percutaneous coronary intervention (PCI) for 
ST elevation myocardial infarction (STEMI) have been demonstrated, but most 
studies were conducted in experienced centres in western world. Experience, 
logistics and patient characteristics may differ in other parts of the world, particularly 
in a starting center.
Methods: Data on all consecutive STEMI patients treated with primary PCI in Cinere 
hospital, Jakarta, Indonesia were collected in a prospective database. 
Results:,Between July 2006 and December 2008, a total of 100 patients with STEMI 
were treated by primary PCI. Mean age was 56.9 ±10.4 years (range 37-82), 88% 
was male. Mean time between onset of chest pain and admission was 369 ± 388 
minutes. The mean time between admission and balloon inflation was 258 minutes. 
Before PCI, 50% of patients had TIMI 0 flow. After primary PCI 94% of patients had 
TIMI 2/3 flow. There were no deaths in the catheterisation room, and no emergency 
coronary bypass surgery was needed as a result of PCI complications. Mean left 
ventricular ejection fraction as measured by echocardiography after 1 day was 48 ± 
12 %.
Conclusions: Outcome after primary PCI at a starting center is excellent in this 
series. Primary PCI was effective in restoration of TIMI flow, without complications. 
Time delay between symptom onset, admission and balloon inflation was long and all 
efforts should be encouraged to shorten this.
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Introduction
Randomized controlled trials, involving more than 7500 patients with ST elevation 
Myocardial Infarction (STEMI), have demonstrated the superiority of primary 
percutaneous coronary intervention (PCI) compared to fibrinolytic therapy (1), with 
the greatest absolute mortality advantage of primary PCI in high-risk patients such as 
those with cardiogenic shock (2, 3). However, almost all these trials were performed 
in the United States or Western Europe in highly experienced centers. Also because 
success and complications of PCI are dependent of the experience of the operator 
and the hospital, it is mandatory to monitor the results of primary PCI in a new 
starting hospital.
In the South Asia region, including Indonesia, both morbidity and mortality due to 
cardiovascular disease is high and it is expected that this will increase even more (4). 
Main causes are the high prevalence of diabetes (5), hypertension (6) and smoking 
(7, 8).
To assess the results of primary PCI, as well as hospital mortality after the procedure 
in a new hospital in Jakarta, Indonesia, we performed a prospective registry.
Patients and Methods
All data on the first 100 consecutive patients treated with primary PCI for STEMI in 
Klinik Kardiovaskular - Cinere Hospital, Jakarta, Indonesia between August 2006 and 
October 2008 were registered in a dedicated database. Cinere Hospital, Jakarta 
started in 2006 with PCI program. They have a close collaboration with the Isala 
klinieken, Zwolle, the Netherlands, and there is always an experienced consultant 
cardiologist from Netherlands in Jakarta.
There was no industry involvement in the design, conduct or analysis of this study.
All patients with STEMI, presenting within 6 hours after symptom-onset, or those 
presenting between 6 and 24 hours if they had persisting chest pain associated with 
clinical evidence of on-going ischemia, were eligible for primary PCI and inclusion in 
the registry.
All patients were pretreated with aspirin, a loading dose of clopidogrel and 
intravenous nitroglycerin and heparin. Treatment with glycoprotein IIb/IIIa inhibitors 
was left to the discretion of the physicians. Stenting of target lesion were performed
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using standard interventional techniques. After the primary PCI all patients were 
treated with guidelines provided medication, including statins and beta-blockers. All 
patients received clopidogrel for at least 6 months.
Statistical Analysis
Statistical analysis were performed with the Statistical Package for the Social 
Sciences (SPSS Inc., Chicago, IL, USA) version 15.0. Continuous data were 
expressed as mean ± standard deviation and categorical data as percentage, unless 
otherwise denoted. Differences between continuous data were performed by 
students t test and the chi-square or Fisher’s exact test were used as appropriate for 
dichotomous data. For all analyses, statistical significance is assumed when the two­
tailed probability value is < 0.05.
RESULTS
Data were collected from 100 patients. Mean age was 56.9 ± 10.4 years (range 37­
82), 88% was male. The mean time between onset of chest pain and admission was 
369 ± 388 minutes. Females were older, 66.3 ± 9.7 years compared to males, 55.6 ± 
9.9 (p=0.001). The time between symptom onset and admission was longer in 
females, 412 ± 462 minutes compared to males 362 ± 380 minutes, but this was not 
statistically significant (p=0.7).
Baseline characteristics of the patients are listed in table 1. The prevalence of 
diabetes, high lipids and smoking was high. Males were more frequently smokers 
(56%) compared to females (8%, p=0.002). Diabetes was more common in females 
(50%) than in males (28%), but this difference was not statistically significant 
(p=0.11). There were many patients with signs of heart failure on admission, 10% 
had heart failure Killip class 3 and 13% had Killip class 4.
In table 2 angiographic findings are summarized. The mean time between admission 
and balloon inflation was 258 minutes with a median time of 163 minutes. Time 
between admission and balloon inflation was significant longer in females, 553 ± 675 
minutes as compared to males, 219 ± 217 minutes (p=0.004).
Of the 100 patients, 33% had multivessel disease. This was (not significant) more 
often observed in males (37%) compared to females (13%, p=0.18). The prevalence
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of multivessel disease was comparable in smokers (39%) and non-smokers (32%) 
and in patients with (33%) and without (35%) diabetes.
The observed TIMI flow in the infarct related vessel before and after PCI is 
summarized in figure 1. The frequency of TIMI flow 0 (occluded vessel) was (not- 
significant) more often observed in males (52%) compared to females (42%, p =
0.49), and in patients with anterior location (54%) as compared to inferior location 
(43%) but comparable between patients with (47%) and without diabetes (52%). 
Mean age of patients with TIMI 0 flow before PCI was 56 ± 10 years compared to 58 
± 11 years of patients with TIMI 1 -3 flow before PCI (p =0.58).
TIMI 2 or 3 flow in the infarct related vessel was achieved in 94% of patients. 
Achieved TIMI 2 or 3 flow was slightly more common in males (95%) than in females 
(83%, p =0.10). Mean age of patients with TIMI 2/3 flow after PCI was 57 ± 11 years 
compared to 54 ± 5 years of patients with TIMI 2/3 flow after PCI (p =0.61). TIMI flow 
2/3 was significant less often observed in patients who had TIMI flow 0 before PCI 
(88%) than in patients with TIMI flow 1-3 before PCI (100%, p =0.01).
There were no deaths in the catheterisation room. Also, no patients required transfer 
for emergency coronary bypass surgery as a result of PCI complications. Mean left 
ventricular ejection fraction as measured by echocardiography after 1 day was 48 ± 
12 %. Mean LV ejection fraction of patients with anterior wall infarction was lower, 
46% ± 12% compared to 52% ± 13% in patients with inferior wall myocardial 
infarction PCI (p =0.05).
DISCUSSION
We describe a high-risk group of patients with STEMI with more than 10% Killip class 
4 on admission. In these first 100 patients with STEMI treated by primary PCI in our 
hospital, it was demonstrated that primary PCI was effective, resulting in restoration 
of TIMI 2/3 flow in more than 90%. Delay between onset of symptoms, admission 
and first balloon inflation was long.
Our results suggest that primary PCI in a starting heart center in Indonesia is safe 
and is effective in achieving reperfusion. However, our results were achieved in the 
setting of a close collaboration with an experienced center. Possibly, this may 
influence the favourable results. Our results confirm the PAMI-No SOS study, that
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showed that primary PCI in high-risk STEMI patients in hospitals without on-site 
cardiac surgery is safe and effective (9). Also other studies in both Western world 
and Asia reported that primary PCI can be safely performed in hospitals without on 
site cardiac surgery (10, 11). However, it is important to monitor results of PCI, 
particularly primary PCI, in small hospitals, since correlation between operator and 
hospital volume and PCI outcomes has been described (12). But, with modern 
techniques, this correlation may be less pronounce, (13). It has also been suggested 
that expertise and experience of the whole professional team, rather than just of the 
individual operator, play a major role (14).
The prevalence of risk factors in our patients was very high, with diabetes 30%, and 
smoking, hypertension or high lipids in almost 50% of patients. Cardiac rehabilitation 
should be an essential part of the contemporary care of these patients after the acute 
phase. Risk factor modification should be achieved by encouraging exercise, 
education, life stile change, counselling, support, and strategies aimed at targeting 
traditional risk factors for cardiovascular disease. Intensive programs for smoking 
cessation should already be started during hospital admission (15). The high 
prevalence of diabetes in our study may be associated with the high prevalence of 
diabetes in the general population in Indonesia.
In our study, there was a long time interval between symptom onset, hospital 
admission and balloon inflation. All these intervals should be shorter. Education in 
the general population should make people more aware of potential cardiac 
symptoms and the importance to seek fast medical care. Ambulance transport should 
be improved, possibly by regional approaches round hospitals with PCI facilities and 
prehospital ECGs transmitted to an emergency department or relying on ambulance- 
based paramedics trained to diagnosis STEMI and to determine which patients 
should be transported directly to specialized PCI centers (16). In-hospital delay was 
in our study mainly because of financial considerations and patient delay because of 
fear for the procedure. General population, government and insurance companies 
should be informed that costs of primary PCI, particularly if performed with only 
balloon, is lower than conservative treatment.
Limitations
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We studied only patients in one hospital, involving only few patients, and we could 
therefore not perform subgroup analyses. Furthermore, selection bias may occur as 
only survivors of STEMI undergoing primary PCI were included in this registry. We 
had no data on patients who had STEMI but were not treated with primary PCI, or 
who were not admitted in the hospital at all. Finally, we had no follow-up data, mainly 
because many patients went back to their referring hospital the day after the primary 
PCI.
Conclusions
Primary PCI for ST elevation Myocardial Infarction is safe and effective at a starting 
heart center in Indonesia, if performed by an experienced team. However, 
prehospital and in-hospital time delay is high, and therefore all efforts should be 
aimed towards reduction in total ischemic time, by developing regional logistics with 
pre-hospital triage and fast track facilities in dedicated PCI centers.
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Table 1 -  General characteristics of 100 patients treated with primary PCI for STEMI 
in Klinik Kardiovaskular, Cinere hospital, Jakarta
N = 100
% or mean ±
SD
Age (years) 56.9 ± 10.4
Male 88
Diabetes 30
High lipids 56
Hypertension 49
Smoking 48
Previous MI 28
Previous PCI 8
Previous Coronary Bypass Surgery 2
Anterior location 60
Admission Creatinin (mg/dl) 1.24 ± 1.09
Killip > 2 on admission 46
Ventricular Fibrillation before angiography 11
Time between onset chest pain and admission
(minutes) 369 ± 388
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Table 2 -  Angiographic findings in 100 patients treated with primary PCI for STEMI in 
Klinik Kardiovaskular Cinere hospital, Jakarta.
N = 100
% or mean ± SD
Time between admission
and balloon inflation (minutes) 258± 317
Multi vessel disease 33
TIMI 0 before angioplasty 50
Bare metal stent 49
Drug Eluting stent 24
TIMI 2/3 flow after angioplasty 94
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Figure 1 - TIMI flow in the infarct related vessel before and after primary PCI in 100
patients
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CHAPTER 9
Primary coronary intervention for ST elevation myocardial 
infarction in Indonesia and the Netherlands: a comparison
Neth Heart J 2009 Nov;17(11 ):418-2
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Abstract
Background: Although the beneficial effects of primary percutaneous coronary 
intervention (PCI) for ST elevation myocardial infarction (STEMI) has been 
demonstrated in a number of trials, most studies were conducted in the western 
countries. Experience, logistics and patient characteristics may differ in other parts of 
the world.
Methods: Consecutive patients treated between January 2008 and October 2008 
with primary PCI in hospital Cinere, Jakarta, Indonesia were compared with those 
treated in the Isala klinieken, Zwolle, the Netherlands
Results: During the study period, a total of 596 patients were treated by primary PCI, 
568 in Zwolle and 28 in Jakarta. Patients in Indonesia were younger (54 vs 63 years), 
more often had diabetes (36% vs 12%) and high lipids and were more often smokers 
(68% vs 31%). Time delay between symptom onset and admission was longer in 
Indonesia. Patients from Indonesia had more often signs of heart failure at 
admission. The time between admission and balloon inflation was longer in 
Indonesia. At angiography, patients from Indonesia had more often multi vessel 
disease. There was no difference in percentage of restoration of TIMI 3 flow by 
primary PCI between the two hospitals.
Conclusions: Patients with STEMI in Indonesia have a higher risk profile compared to 
the Netherlands, according to prevalence of coronary risk factors, signs of heart 
failure, multivessel disease and patient delay. Time delay between admission and 
balloon inflation was much longer in Indonesia, because of both logistic and financial 
reasons.
Keywords: developping countries, Asia, Infarction
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Introduction
The most important therapeutic goal in the treatment of patients with ST elevation 
Myocardial Infarction (STEMI) is achievement of early and complete reperfusion of 
the infarct-related vessel. Effective reperfusion can be achieved by either fibrinolytic 
therapy or primary percutaneous coronary intervention (PCI) without antecedent 
fibrinolysis. A total of 23 randomized controlled trials, involving more than 7500 
patients have demonstrated the superiority of primary PCI over fibrinolytic therapy 
(1), with the absolute mortality advantage of primary PCI greatest in high-risk patients 
such as those with cardiogenic shock (2, 3). However, almost all these trials were 
performed in the United States or Western Europe. The situation and the efficacy of 
primary PCI may differ in other parts of the world, with regards to logistics, 
experience of PCI centres and patient characteristics. More insights in potential 
differences between these regions and the western world are important to estimate 
whether primary PCI will also be effective in these countries.
It is expected that the cardiovascular mortality will increase in the South East Asian 
region (4). Also in Indonesia, both morbidity and mortality due to coronary artery 
disease is high. This may be caused by a high prevalence of diabetes (5), 
hypertension (6), and smoking (7, 8). In a developing country like Indonesia, probably 
only a minority of patients with STEMI is treated with primary PCI. But procedures as 
well as patients who are treated with primary PCI may also differ from the Western 
world. To compare treatment with primary PCI in Europe (the Netherlands) and 
Indonesia, we performed a prospective registry in two hospitals.
Patients and methods
All consecutive patients treated with primary PCI for STEMI in either hospital Cinere, 
Jakarta, Indonesia or the Isala klinieken, Zwolle, the Netherlands between January 
and October 2008 were registered in a dedicated database. The Isala klinieken, 
Zwolle is a hospital with a long experience with primary PCI. Hospital Cinere, Jakarta 
started in 2006 with PCI, but has a close collaboration with the Isala klinieken,
Zwolle, and there is always an experienced consultant cardiologist and nursing staff 
from Zwolle working in Jakarta.
There was no industry involvement in the design, conduct or analysis of the study.
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All patients with STEMI, presenting within 6 hours after symptom-onset, or those 
presenting between 6 and 24 hours if they had persisting chest pain associated with 
clinical evidence of on-going ischemia, were considered eligible for primary PCI and 
inclusion in the registry.
All patients were pretreated with aspirin, a loading dose of clopidogrel and 
intravenous nitroglycerin and heparin. Treatment with glycoprotein IIB/IIIA inhibitors 
was left to the discretion of the physicians. Stenting of target lesion was performed 
using standard interventional techniques. After the primary PCI all patients were 
treated with guidelines provided medication, including statins and beta-blockers. All 
patients received clopidogrel for at least 6 months.
Statistical analysis
Statistical analysis was performed with the Statistical Package for the Social 
Sciences (SPSS Inc., Chicago, IL, USA) version 15.0. Continuous data were 
expressed as mean ± standard deviation and categorical data as percentage, unless 
otherwise denoted. Differences between continuous data were performed by 
students t test and the chi-square or Fisher’s exact test were used as appropriate for 
dichotomous data. For all analyses, statistical significance was assumed when the 
two-tailed probability value was < 0.05.
Results
Data were collected in 596 consecutive patients. The mean age was 62.5 years 
(range 28-96) and 75% were male. The mean time between onset of chest pain and 
admission was 225 (± 215) minutes. Females were older, 66.2 (± 13.1) years 
compared to males, 61.2 (± 12.6). The time between symptom onset and admission 
was comparable in females (230 ± 217 minutes) and males (223 ± 214 minutes). 
During the study period, a total of 568 patients in Zwolle and 28 patients in hospital 
Cinere were treated with primary PCI for STEMI. Baseline characteristics of the 
patients are listed in table 1. Patients from Indonesia were younger, with a trend to 
more males. The prevalence of diabetes, high lipids and smoking was higher in 
Indonesian patients. Time between symptom onset and hospital admission was 
longer in Indonesian patients. In table 2 angiographic measurements are 
summarized. Time from hospital admission to balloon inflation was much longer in
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Indonesia. Furthermore, more patients from Indonesia had multi vessel disease. The 
other angiographic characteristics were not different between patients from the 
Netherlands and Indonesia. Death within 30 days after admission was observed in 24 
patients in the Netherlands (4.2%) and in 1 patient (3.6%) in Indonesia (NS).
Discussion
We found important differences between patients treated with primary PCI for STEMI 
in Indonesia and the Netherlands. Patients in Indonesia had a higher risk profile 
compared to the Netherlands, with regards to prevalence of coronary risk factors, 
signs of heart failure and patient delay. Although primary PCI was effective in 
restoration of TIMI 3 flow in both countries, time delay between admission and 
balloon inflation was longer in Indonesia.
Clinical Implications
Our results suggest that many factors can be improved to reduce morbidity and 
mortality due to STEMI in Indonesia. First, both health care professionals and 
politicians should still focus on primary prevention. The high prevalence of 
unfavourable risk factors in our Indonesian patients was also observed in the 
Indonesian general population previously (9). Patients from Indonesia had a twofold 
prevalence of smoking in our study. The prevalence of smoking is still high in 
Indonesia, although there have been campaigns against smoking, particularly 
because it has been shown that there are no ethnic differences in the benefits of 
quitting smoking (10). The Indonesian Ministry of Health makes already use of 
traditional media such as the wayang kulit (shadow puppet theatre) and warnings 
about the harmful effects of (passive) smoking. Also the Indonesian Heart 
Foundation and several foundations as the Foundation's No-Smoking Leaders Group 
(Lembaga Menanggulangi Masalah Merokok, known as Lembaga M3) and the 
Wanita Indonesia Tanpa Tembakau (WITT) or Indonesian Women Without Tobacco 
are fighting against smoking. Probably,even more aggressive public health efforts to 
limit tobacco use are urgently needed in Indonesia now. Also, the prevalence of 
diabetes was high in our study. This may be related to a high prevalence of diabetes 
in the general population in Indonesia, which may be in part associated with the 
metabolic syndrome. Studies of people living in rural areas of East Java and Bali 
show an increasing prevalence of 1.5% in 1982 to 5.7% in 1995 among the urban
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population. Comparative studies indicate that metabolic responses to obesity may be 
greater in South and East Asians than their western counterparts at given Body Mass 
Indexes (11,12) It was previously suggested that early detection of asymptomatic 
diabetes in Indonesia should be encouraged, either at the hospital or doctor's private 
office (13). Furthermore, it has been demonstrated that the management of type 2 
diabetes in the Western Pacific Region varies widely, with often untreated 
hypertension and microalbuminuria (14).
A second important goal in the treatment of patients with STEMI in Indonesia should 
be to reduce the time between symptom onset and first balloon inflation. There is a 
strong association between time delay and mortality in patients with STEMI treated 
by primary PCI (15). This can be separated in delay between symptom onset and 
hospital admission and in delay between admission and balloon inflation. There can 
be several strategies to decrease time delays (16). All steps should be considered for 
improvement, including the patient’s ability to recognize their symptoms and to 
promptly contact the medical system, the time necessary to transport the patient to 
the hospital, the decision process on arrival, and the requisite time to implement the 
reperfusion strategy. Possibly, in Indonesia particularly ambulance transport systems 
can be improved, with regional approaches round hospitals with PCI facilities and 
prehospital ECGs transmitted to an emergency department or relying on ambulance- 
based paramedics trained to diagnosis STEMI and to determine which patients 
should be transported directly to specialized PCI centers (17).
More importantly, in Indonesia much delay and even the impossibility to offer primary 
PCI to patients with STEMI may be influenced by financial considerations. About 80 
percent of the Indonesian population has no health insurance coverage. Although the 
insurance scheme for civil servants (Askes) may have had a strongly positive impact 
on access of poor patients to medical care (18), access to especially all hospital 
services is still low for the middle and low-income patients (19). This is difficult to 
solve on the short time, but should be an effort of government, insurance companies, 
medical professionals and aid from the Western world. It should be kept in mind that 
the costs of primary PCI, particularly if performed with "stand-alone" balloon- 
angioplasty, may be lower than conservative treatment or thrombolysis (20).
Limitations
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We studied only patients in two hospitals. Particularly in Indonesia, a very large 
country, the results may have been different in other regions or hospitals.. 
Geographical variation may be of importance, due to differences in ethnics, race, 
culture and lifestyle. Moreover, we included only few patients from Indonesia, and we 
could therefore not perform subgroup analyses. Finally and maybe most importantly, 
health economics differ greatly between Indonesia and the Netherlands. This may 
have introduced confounding factors that cannot be detected by this survey. Because 
of this selection bias, we are now scheduling a larger, prospective registry, with also 
patients from the university hospital in Jakarta. However, also then financial reasons 
may still cause (additional) selection bias, since only selected patients with 
myocardial infarction are admitted to a hospital, and of those only happy few may be 
treated by primary PCI.
Conclusions
Patients with STEMI in Indonesia have a higher risk profile compared to Netherlands, 
according to prevalence of coronary risk factors, signs of heart failure and patient 
delay. Although primary PCI was effective in both countries with regard to restoring 
TIMI 3 flow, time delay between admission and balloon inflation was longer in 
Indonesia. Treatment of STEMI can be improved in Indonesia and this should be a 
combined effort of both government and health care professionals.
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Table 1 -  Differences between patients treated with primary PCI for STEMI in 
hospital Cinere, Jakarta and Isala klinieken, Zwolle
Isala klinieken, Hospital Cinere, P value
Zwolle, N = 568 Jakarta, N = 28
% or mean ± SD % or mean ± SD
Age (years) 62.9 ± 12.8 53.8 ± 11.6 0.001
Male 75 86 0.19
Diabetes 12 36 0.001
Family history of heart disease 37 32 0.64
High lipids 19 46 0.001
Hypertension 42 46 0.65
Smoking 31 68 0.01
Previous MI 11 18 0.27
Anterior location 39 54 0.13
Killip > 2 on admission 8 52 0.001
Time between onset chest pain 214 ± 202 413 ± 325 0.001
and admission (minutes)
Systolic blood pressure on 133 ± 26 117 ± 23 0.002
admission (mm Hg)
Diastolic blood pressure on 81 ± 17 76 ± 14 0.12
admission
Heart rate on admission (beats 76.8 ± 19.6 83.4 ± 27.3 0.09
per minute)
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Table 2 -  Angiographic findings in patients treated with primary PCI for STEMI in 
hospital Cinere, Jakarta or Isala klinieken, Zwolle
Isala klinieken, 
Zwolle, N = 568
Hospital Cinere, 
Jakarta, N = 28
P value
% or mean ± SD % or mean ± SD
Time between admission and 49 ± 33 189 ± 127 0.001
balloon inflation (minutes)
M ulti vessel disease 51 75 0.01
Infarct related vessel:
LAD 39 46 0.40
RCA 39 39 0.99
TIM I 0 before PCI 59 68 0.34
Stenting 73 71 0.82
Only one stent used 80 75 0.62
TIM I 3 flow after PCI 93 85 0.15
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CHAPTER 10
Summary & conclusions
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In Indonesia, every year thousands of people have a heart attack and thousands of 
people will die because of this heart attack, many because they are too late for 
medical care or because medical care is sub optimal.
In the current thesis, several aspects of optimising treatment of a heart attack, ST 
elevation Myocardial Infarction (STEMI) are discussed and assessed, with particular 
attention for improvement of treatment in Indonesia.
In chapter 1, a brief introduction about the subject and the background of the thesis 
is given. From data from the WHO, it is shown that the incidence of cardiovascular 
disease in Indonesia is very high. This may be caused by the high prevalence of 
smoking and (not or not well treated) diabetes, hypertension and elevated cholesterol 
levels. Based on the increasing prevalence of these unfavourable risk factors, the 
burden of cardiovascular disease is a big problem in Indonesia.
In chapter 2, modern treatment of STEMI is summarized. Treatment starts with a fast 
and good diagnosis and if possible medical treatment in the ambulance. The next 
goal in the treatment is timely, complete and sustained reperfusion of the infarct 
related vessel. Although thrombolytics can be considered in selected patients and if 
percutaneous coronary intervention (PCI) is not available, in the majority of patients 
primary PCI should be the first choice. After reperfusion therapy, patients should be 
treated with antiplatelet medication, beta-blocker, lipid lowering drugs and ACE- 
inhibitors in selected patients. Cardiac rehabilitation should be offered to all patients 
and focus on life style modification, including smoking cessation.
In chapter 3, the glycoprotein (GP) IIb/IIIa inhibitor tirofiban for use in patients with 
myocardial infarction is discussed in more detail. Tirofiban is a small molecule GP 
IIb/IIIa receptor inhibitor. If discontinued, the action of tirofiban is faster reversed as 
abciximab, another GP IIb/IIIa inhibitor. The dose of tirofiban varies between low 
(bolus of 0.4 Mg/kg administered over 30 minutes followed by an infusion of 0.10 
Mg/kg/min), intermediate (bolus of 10 Mg/kg administered over 3minutes followed by 
an infusion of 0.15Mg/kg/min) and high (bolus of 25 Mg/kg administered over 3 
minutes followed by an infusion of 0.15Mg/kg/min). Especially the high dose 
administration may be beneficial in patients with STEMI undergoing primary PCI. 
There is no indication for tirofiban in patients treated with thrombolysis. Patients with 
Non-ST Elevation Myocardial Infarction requiring PCI are most likely to achieve
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benefit from tirofiban, when they have ongoing ischemia and/or dynamic ECG 
changes. It is stated that the risk of serious bleeding with tirofiban is low and there is 
a very low risk of thrombocytopenia.
In chapter 4, the potential benefits of use of stents in primary PCI are assessed. 
Although in previous studies in patients with primary PCI stenting was associated 
with a reduced risk of reinfarction and target vessel revascularization, it was less 
clear whether stenting reduced also mortality when compared to balloon angioplasty. 
To assess the potential association between mortality and stenting in primary PCI in 
daily practise, analyses of a prospective registry from Zwolle, the Netherlands, were 
performed. Primary PCI was performed in 4299 patients, of whom 2571 patients 
(60%) were treated by (bare metal) stenting. There were no differences in age, 
gender, infarct location or diabetes between the two groups, but patients in the 
balloon group had more often previous myocardial infarction and multi vessel 
disease, and had a longer duration between symptom start and admission. The 
combined end-point of death or re-infarction after 30 days was 7.2% in the balloon 
group vs 5.6% in the stent group (p=0.03). After one year follow-up, mortality in the 
balloon group was 7.9%, compared to 5.8% in the stent group (p=0.007). After 
adjusting for differences in age, gender, previous myocardial infarction, patient delay 
and multi vessel disease, use of a stent was still associated with a decreased risk of 
one-year mortality, with OR 0.77, 95% CI 0.61 -  0.98. It was concluded that in 
patients undergoing primary PCI for STEMI, use of stents in daily practise is 
associated with a decreased mortality.
In chapter 5, two different drug-eluting stents are compared in patients with primary 
PCI. As compared to bare metal stent, both Sirolimus (SES) and paclitaxel (PES) 
eluting stents have been shown to improve angiographic and clinical outcomes after 
PCI in elective procedures and patients with STEMI. Aim of the current study was to 
compare SES to PES among STEMI patients undergoing primary PCI. Patients with 
STEMI were randomized 1:1 to receive the SES (n=196) or PES (n=201). Primary 
end point was late lumen loss at 9 months follow-up by quantitative coronary 
angiography. Secondary end points were major adverse cardiac clinical events 
(death, re-infarction, target vessel revascularization) at 1, 9 and 12 months. A total of 
397 patients with STEMI were randomized. The two groups had comparable baseline
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clinical and angiographic characteristics. Mortality was low, 1.5% after 30 days, 2.3 
% after 9 months and 3.1% after one year. There was no difference in any clinical 
outcome at any follow-up period between the two treatment groups. Follow-up 
angiography was completed in 272 of 397 patients (69 percent). The mean (SD) in­
stent late loss was 0.01 (0.42) mm in the sirolimus group vs 0.21 (0.50) mm in the 
paclitaxel group (difference, -0.20 mm, P 0.001).
It was concluded that in patients with STEMI, primary PCI with SES results in less 
late loss compared to paclitaxel eluting stents. However, these benefits did not 
translate into significant reduction in MACE at one-year follow-up.
In chapter 6, a meta-analysis is presented of all trials comparing Rapamycin eluting 
stents (RES) and paclitaxel eluting stents (PES) in patients undergo percutaneous 
coronary intervention. Because many individual studies are small, it is not yet clear 
whether there are any differences between RES and PES with regard to clinical 
outcome. Systematic searches were conducted of randomised controlled trials 
(RCTs) comparing RES with PES in MEDLINE and the Cochrane Database of 
systematic reviews. Information on study design, inclusion and exclusion criteria, 
number of patients, and clinical outcome was extracted by two investigators. 
Disagreements were resolved by consensus. The primary outcome was re­
intervention, target lesion revascularisation (TLR) and target vessel revascularization 
(TVR). Stent re-stenosis, myocardial infarction (MI) and all cause mortality were 
secondary end points. Twenty one RCTs of RES versus PES with a total number of 
10,147 patients were included in this meta-analysis. Indication for angioplasty was 
either acute coronary syndrome or stable angina. Mean follow-up period ranged from 
6 to 24 months. Rates of TLR were 4.9% vs. 7.0%; p=0.0009 and rates of TVR were 
5.1 vs. 8.3%; p<0.001 for RES vs. PES, respectively. The incidence of stent re­
stenosis was 3.9% for RES vs. 5.3% for PES; p=0.004. Rates of MI and all cause 
mortality were comparable. It was concluded that, as compared to PES, RES seems 
to be associated with a lower risk of re-intervention and stent re-stenosis. The risk of 
myocardial infarction and all cause death were similar between the 2 stents.
The safety of the routine use of a new endothelial progenitor cells antibody-coated 
stent in patients with primary PCI is assessed in chapter 7. Although endothelial 
progenitor cell (EPC) capture stents may be safe and may potentially prevent stent
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thrombosis and restenosis, there are only limited data on its use in primary PCI. Data 
on consecutive patients with STEMI treated with the endothelial progenitor cells 
antibody-coated stent (Genous Bio-Engineered R Stent) were collected in a 
prospective registry. Clinical follow-up was performed at 30-days and at 1-year. 
MACE was defined as the combined end point of death, recurrent MI, stent 
thrombosis or additional revascularisation by either PCI or CABG. From January to 
September 2008, a total of 430 consecutive STEMI patients were included in the 
registry. Of these, 9% had diabetes and 35% had anterior infarction. At angiography, 
55% of the patients had TIMI 0 flow before PCI. More than one stent was necessary 
in 20.2% of patients. TIMI 3 flow was achieved in 94% of patients. Acute stent 
thrombosis occurred in 1.2%. The incidence of events after one year follow-up was 
low, with a total mortality of 3.7% and the incidence of late stent thrombosis 0.8%. 
Predictors of MACE up to one year were higher age, not-smoking, small stent 
diameter, no TIMI 3 flow after PCI and use of an intra-aortic balloon pump.
It was concluded that use of the endothelial progenitor cells antibody-coated Genous 
stent is safe and associated with a low event rate. Longer follow-up studies are 
necessary to confirm its long-term efficacy.
In chapter 8, the first 100 patients treated with primary PCI in Klinik Kardiovaskular 
hospital Cinere are described. Primary PCI may be very effective, but most studies 
were conducted in experienced centres in western world. Experience, logistics and 
patient characteristics may differ in other parts of the world, particularly in a starting 
center. Data on all 100 consecutive patients treated with primary PCI in Cinere 
hospital, Jakarta, Indonesia were collected in a prospective database between July 
2006 and December 2008. Mean age was 57 years (range 37-82), 88% was male. 
Mean time between onset of chest pain and admission was 369 minutes. The mean 
time between admission and balloon inflation was 258 minutes. Before PCI, 50% of 
patients had TIMI 0 flow. After primary PCI, 94% of patients had TIMI 2/3 flow. There 
were no patients dying in the catheterisation room. Also, no patients required transfer 
for emergency coronary bypass surgery as a result of PCI complications. Mean left 
ventricular ejection fraction as measured by echocardiography after 1 day was 48 %. 
It was concluded that primary PCI was effective in restoration of TIMI flow, without 
complications. Time delay between symptom onset, admission and balloon inflation 
was long and all efforts should be encouraged to shorten this.
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In chapter 9, consecutive patients treated between January 2008 and October 2008 
with primary PCI in hospital Cinere, Jakarta, Indonesia were compared with those 
treated in the same period in the Isala klinieken, Zwolle, the Netherlands. During the 
study period, a total of 596 patients were treated by primary PCI, 568 in Zwolle and 
28 in Jakarta. Patients in Indonesia were younger (54 vs 63 years), more often had 
diabetes (36% vs 12%) and high lipids and were more often smokers (68% vs 31%). 
Time delay between symptom onset and admission was longer in Indonesia. Patients 
from Indonesia had more often signs of heart failure at admission. The time between 
admission and balloon inflation was longer in Indonesia. At angiography, patients 
from Indonesia had more often multi vessel disease. There was no difference in 
percentage of restoration of TIMI 3 flow by primary PCI between the two hospitals.
It is concluded that patients with STEMI in Indonesia have a higher risk profile 
compared to the Netherlands, according to prevalence of coronary risk factors, signs 
of heart failure, multivessel disease and patient delay. Time delay between 
admission and balloon inflation was much longer in Indonesia, because of both 
logistic and financial reasons.
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CHAPTER 11
Samenvatting & conclusies
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In Indonesië sterven ieder jaar duizenden mensen tengevolge van een hartinfarct 
(myocardinfarct), velen doordat de behandeling te laat komt of onvoldoende is.
In dit proefschrift worden verschillende aspecten onderzocht om de behandeling van 
een ST-elevatie myocardinfarct (STEMI) te verbeteren, met in het bijzonder aandacht 
voor het verbeteren van de behandeling in Indonesië.
In hoofdstuk 1, wordt een korte inleiding over het onderwerp gegeven en enkele 
achtergronden geschetst. Gegevens van de Wereld Gezondheids Organisatie 
(WHO) tonen aan dat de incidentie van cardiovasculaire ziekten in Indonesië hoog is. 
Dit wordt onder andere veroorzaakt door de hoge prevalentie van roken, (niet 
optimaal behandelde) diabetes, hypertensie en verhoogd cholesterol. Door deze 
hoge (en nog toenemende) prevalentie van risicofactoren, is de omvang van 
cardiovasculaire ziekten in Indonesië een groot probleem.
In hoofdstuk 2, wordt de huidige behandeling van een ST Elevatie Myocardinfarct 
beschreven en samengevat. De behandeling begint met een snelle en goede 
diagnose, en behandeling in de ambulance. Het volgende doel is het afgesloten 
infarct vat snel, compleet en blijvend te openen. Hoewel in geselecteerde patiënten 
thrombolyse van waarde kan zijn, met name als een primaire Percutane Coronaire 
Interventie (PCI) niet mogelijk is, is voor de meeste patiënten met een STEMI een 
primaire PCI de beste keus. Na reperfusie therapie, zal optimale medicatie moeten 
worden gegeven: thrombocyten aggregatie remmers (aspirine, clopidogrel), 
bètablokkers, lipiden verlagende middelen (statinen) en ACE inhibitors. Alle patiënten 
zullen een revalidatie traject moeten krijgen, met focus op levensstijl aanpassingen, 
inclusief stoppen met roken.
In hoofdstuk 3, wordt het gebruik van de glycoprotein (GP) IIb/IIIa inhibitor tirofiban 
bij patiënten met een hartinfarct meer in detail beschreven. Tirofiban is een laag 
moleculaire GP IIb/IIIa receptor inhibitor. Na staken van tirofiban is de werking sneller 
verdwenen dan van abciximab, een andere GP IIb/IIIa inhibitor, en dit kan gunstig 
zijn bij het optreden van een bloeding of als een patiënt een operatie moet 
ondergaan. De dosering van tirofiban varieert tussen laag (bolus van 0.4 Mg/kg 
toegediend gedurende 30 minuten gevolgd door een infuus van 0.10 Mg/kg/min),
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gemiddeld (bolus van 10 Mg/kg gedurende 3 minuten, gevolgd door een infuus van 
0.15^g/kg/min) and hoog (bolus van 25 Mg/kg gedurende 3 minutes gevolgd door een 
infuus van 0.15Mg/kg/min).
Vooral de hoge dosis kan gunstig zijn bij patiënten met STEMI die een primaire PCI 
ondergaan. Er is geen indicatie voor tirofiban bij patiënten die behandeld worden met 
trombolyse. Patiënten met non-ST elevatie myocardinfarct bij wie een PCI nodig is, 
hebben waarschijnlijk het meest profijt van tirofiban, wanneer zij de langdurige 
ischemie en / of dynamische ECG-veranderingen hebben. Het risico van ernstige 
bloedingen met tirofiban is laag en er is een zeer laag risico van trombocytopenie.
In hoofdstuk 4 worden de potentiële voordelen van het gebruik van stents in 
primaire PCI bestudeerd. Hoewel in eerdere studies bij patiënten met primaire PCI 
het gebruik van een stent was geassocieerd met een verlaagd risico van re-infarct en 
revascularisatie, was het minder duidelijk of stenting ook mortaliteit in vergelijking 
met ballondilatatie vermindert. Voor het beoordelen van de mogelijke associatie 
tussen sterfte en stenting in primaire PCI in de dagelijkse praktijk, werden de 
analyses van een prospectieve registratie uit Zwolle, Nederland, uitgevoerd. Primaire 
PCI werd uitgevoerd in 4299 patiënten, van wie 2571 patiënten (60%) werden 
behandeld door (bare metal) stent. Er waren geen verschillen in leeftijd, geslacht, 
infarctplaats of diabetes tussen de twee groepen, maar de patiënten in de ballon 
groep had vaker een eerder myocardinfarct en meertakslijden, en hadden een 
langere duur tussen start van symptomen en opname. Het gecombineerde eindpunt 
van overlijden of een nieuw infarct na 30 dagen was 7,2% in de ballon groep versus 
5,6% in de stent-groep (p = 0,03). Na een jaar follow-up was de sterfte in de ballon 
groep 7,9%, tegenover 5,8% in de stent-groep (p = 0,007). Na correctie voor 
verschillen in leeftijd, geslacht, doorgemaakt myocardinfarct, tijd tussen klachten en 
opname en meertakslijden, was het gebruik van een stent nog steeds geassocieerd 
met een verminderd risico van 1-jaarsterfte, met OR 0,77, 95% CI 0,61 - 0,98. Er 
werd geconcludeerd dat bij patiënten die een primaire PCI STEMI ondergaan, het 
gebruik van stents in de dagelijkse praktijk geassocieerd is met een verminderde 
mortaliteit.
In hoofdstuk 5 worden twee verschillende drug-eluting stents vergeleken bij 
patiënten die wegens STEMI worden behandeld met primaire PCI. In vergelijking met
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bare metal stents, is van zowel de sirolimus (SES) als de paclitaxel (PES) eluting 
stents aangetoond dat angiografische en klinische resultaten verbeteren na een PCI 
bij electieve procedures en patiënten met STEMI. Doel van de huidige studie was om 
SES te vergelijken met PES bij STEMI-patiënten die primaire PCI ondergaan. 
Patiënten met STEMI werden 1:1 gerandomiseerd naar de SES (n = 196) of PES (n 
= 201). Primaire eindpunt was lumen reductie na 9 maanden follow-up, gemeten met 
behulp van kwantitatieve coronaire angiografie. Secundaire eindpunten waren 
belangrijke cardiovasculaire klinische eindpunten (overlijden, re-infarct, 
revascularisatie van het infarctvat) na 1, 9 en 12 maanden. Een totaal van 397 
patiënten met STEMI werden gerandomiseerd. De twee groepen hadden 
vergelijkbare klinische en angiografische kenmerken. De sterfte was laag, 1,5% na 
30 dagen, 2,3% na 9 maanden en 3,1% na een jaar. Er was geen verschil in 
klinische uitkomst op elk follow-up moment tussen de twee behandelingsgroepen. 
Follow-up angiografie werd voltooid in 272 van 397 patiënten (69 procent). De 
gemiddelde (SD) in-stent lumen reductie was 0,01 (0.42) mm in de sirolimus groep 
versus 0,21 (0,50) mm in de paclitaxel-groep (verschil -0,20 mm, P 0,001). 
Geconcludeerd werd dat bij patiënten met STEMI, primaire PCI met SES resulteert in 
minder lumen reductie, in vergelijking met paclitaxel eluting stents. Echter, deze 
voordelen leidden niet tot aanzienlijke vermindering van MACE na een jaar follow-up.
In hoofdstuk 6 wordt een meta-analyse gepresenteerd van alle onderzoeken die 
Rapamycin stents (RES) en paclitaxel-eluting stents (PES) vergelijken bij patiënten 
die een primaire PCI ondergingen wegens een STEMI. Omdat veel afzonderlijke 
studies klein zijn, was het nog niet duidelijk of er verschillen zijn tussen de RES en 
PES met betrekking tot de klinische uitkomst. Een systematische onderzoek werd 
uitgevoerd van alle gerandomiseerde gecontroleerde studies (RCTs) die RES met 
PES vergeleken en gepubliceerd waren in MEDLINE of de Cochrane Database van 
systematische reviews. Informatie over de onderzoeksopzet, inclusie en exclusie 
criteria, het aantal patiënten, en het klinische resultaat werd geëxtraheerd door twee 
onderzoekers. Meningsverschillen werden opgelost door consensus. De primaire 
uitkomstmaat was hernieuwde revascularisatie van het infarctvat (TLR). Stent re­
stenose, myocardinfarct (MI) en mortaliteit door alle oorzaken waren secundaire 
eindpunten. Eenentwintig RCT's van SES ten opzichte van PES met een totaal 
aantal van 10.147 patiënten werden opgenomen in deze meta-analyse. Indicatie voor
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angioplastiek was ofwel acuut coronair syndroom of stabiele angina pectoris. De 
follow-up periode varieerde van 6 tot 24 maanden. Het voorkomen van TLR was 
4,9% vs 7,0%, p = 0,0009 en van TVR 5,1 vs 8,3%; p <0,001 voor RES vs PES, 
respectievelijk. De incidentie van stent re-stenose was 3,9% voor RES versus 5,3% 
voor PES, p = 0,004. De incidentie van MI en mortaliteit door alle oorzaken waren 
vergelijkbaar. Geconcludeerd werd dat, in vergelijking met PES, RES lijkt te zijn 
geassocieerd met een lager risico van re-interventie en re-stent stenose. Het risico 
van myocardinfarct en overlijden ongeacht oorzaak waren vergelijkbaar tussen de 2 
stents.
De veiligheid van het routinematig gebruik van een nieuwe endotheliale 
voorlopercellen antilichaam-gecoate stent bij patiënten met primaire PCI is 
onderzocht in hoofdstuk 7. Hoewel door endotheliale voorlopercellen (EPC) af te 
vangen stents voordeel kunnen bieden en mogelijk stent trombose en restenose 
voorkomen, zijn er slechts gegevens beperkt bij het gebruik ervan bij de primaire 
PCI. Gegevens over opeenvolgende patiënten met STEMI behandeld met de 
endotheliale voorlopercellen antilichaam-gecoate stent (Genous Bio-engineered R 
stent) werden verzameld in een prospectieve registratie. Klinische follow-up werd 
uitgevoerd na 30-dagen en na 1-jaar. MACE werd gedefinieerd als het 
gecombineerde eindpunt van overlijden, recidiverend MI, stent trombose of 
aanvullende revascularisatie door een PCI of CABG. Van januari tot september 2008 
werden in totaal 430 opeenvolgende STEMI-patiënten opgenomen in de registratie. 
Van deze patiënten had 9% diabetes en 35% had anterior infarct. Bij angiografie, 
bleek 55% van de patiënten TIMI 0 flow vóór PCI te hebben. Meer dan 1 stent was 
nodig bij 20,2% van de patiënten. TIMI 3 flow werd bereikt bij 94% van de patiënten. 
Acute stent trombose werd waargenomen bij 1,2%. De incidentie van gebeurtenissen 
na een jaar follow-up was laag, met een totale mortaliteit van 3,7% en de incidentie 
van late stent trombose 0,8%. Voorspellers van MACE na een jaar waren hogere 
leeftijd, niet-rokers, kleine stent diameter, geen TIMI 3 flow na PCI en het gebruik van 
een intra-aortale ballonpomp.
Geconcludeerd werd dat het gebruik van de endotheliale voorlopercellen 
antilichaam-gecoate stent Genous veilig is en geassocieerd met een lage incidentie 
van MACE tijdens 1 jaar follow-up. Langere follow-up studies zijn nodig om de 
werkzaamheid op lange termijn te bevestigen.
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In hoofdstuk 8 worden de eerste 100 patiënten die behandeld werd middels primaire 
PCI in Klinik Kardiovaskular ziekenhuis Cinere, Jakarta, Indonesie, beschreven. 
Primaire PCI zou zeer effectief kunnen zijn, maar de meeste studies werden 
uitgevoerd in ervaren centra in de westerse wereld. Ervaring, logistiek en patiënt 
kenmerken kunnen verschillen in andere delen van de wereld, met name in een 
beginnende centrum. Gegevens over alle eerste 100 opeenvolgende patiënten 
behandeld met primaire PCI in Cinere ziekenhuis, Jakarta, Indonesië werden 
verzameld in een prospectieve database tussen juli 2006 en december 2008. De 
gemiddelde leeftijd was 57 jaar (variërend tussen 37 en 82), 88% was man. 
Gemiddelde tijd tussen begin van de pijn op de borst en opname was 369 minuten. 
De gemiddelde tijd tussen opname en opblazen van de ballon was 258 minuten.
Voor de PCI had 50% van de patiënten TIMI 0 flow. Na de primaire PCI, 94% van de 
patiënten had TIMI 2 / 3 flow. Er stierven geen patiënten in de katheterisatie kamer. 
Ook geen van de patiënten behoefden een spoed coronaire bypass-operatie als 
gevolg van een PCI-complicatie. De gemiddelde linker ventrikel ejectiefractie zoals 
gemeten door middel van echocardiografie na 1 dag was 48%.
Geconcludeerd werd dat ook in een beginnend hartcentrum in Indonesië, primaire 
PCI effectief was in het herstel van de TIMI flow in het infarctvat, zonder 
complicaties. Tijdvertraging tussen aanvang van de symptomen, de 
ziekenhuisopname en opblazen van de ballon was lang en alle inspanningen moeten 
worden aangemoedigd om dit te verkorten.
In hoofdstuk 9 werden opeenvolgende patiënten, behandeld tussen januari 2008 en 
oktober 2008 met primaire PCI in het ziekenhuis Cinere, Jakarta, Indonesië 
vergeleken met degenen die behandeld werden in dezelfde periode in de Isala 
klinieken, Zwolle, Nederland. Gedurende de studie periode werden in totaal 596 
patiënten behandeld met primaire PCI, 568 in Zwolle en 28 in Jakarta. Patiënten in 
Indonesië waren jonger (54 vs 63 jaar), hadden vaker diabetes (36% vs 12%), vaker 
verhoogde lipiden en waren vaker rokers (68% vs 31%). Tijd tussen aanvang van de 
symptomen en opname was langer in Indonesië. Patiënten uit Indonesië, hadden 
vaker tekenen van hartfalen bij opname. De tijd tussen opname en opblazen van de 
ballon was langer in Indonesië. Bij angiografie, patiënten uit Indonesië, hadden vaker 
meertakslijden. Er was geen verschil in percentage van de restauratie van TIMI 3 
flow door primaire PCI tussen de twee ziekenhuizen.
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Geconcludeerd wordt dat patiënten met STEMI in Indonesië een hoger risicoprofiel 
hebben ten opzichte van Nederland, wat betreft de prevalentie van coronaire 
risicofactoren, tekenen van hartfalen, meervatslijden ziekte, en lange tijd tussen 
klachten en behandeling. Tijd tussen opname en opblazen van de ballon was veel 
langer in Indonesië, zowel vanwege logistieke en financiële redenen.
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Abstrak dan kesimpulan dalam bahasa
Indonesia
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Di Indonesia, setiap tahun puluhan ribu orang meninggal oleh karena serangan 
jantung, kebanyakan kematian ini disebabkan oleh keterlambatan pelayanan 
kesehatan atau pelayanan kesehatan yang belum memadai.
Disertasi ini membahas beberapa aspek untuk mengoptimalkan penanganan 
serangan jantung akut atau ST-segmen Elevasi Miocard Infark (STEMI) terutama 
dalam rangka memperbaiki penanganan di Indonesia.
Dalam bab 1, diberikan pendahuluan singkat tentang tema dan latar belakang 
disertasi ini. Data WHO menunjukkan bahwa insiden penyakit kardiovaskular di 
Indonesia tinggi. Hal ini dapat disebabkan oleh tingginya prevalensi merokok dan 
(tidak atau kurang baiknya penanganan) diabetes, hipertensi dan kadar kolesterol 
yang tinggi. Berdasarkan tingginya faktor risiko ini, beban penyakit kardiovaskular 
menjadi masalah besar di Indonesia.
Dalam bab 2, diringkas tentang penanganan mutakhir ST-segmen Elevasi Miokard 
Infark. Penanganan dimulai dengan penegakan diagnosa yang cepat dan baik dan 
bila memungkinkan pengobatan diawali di ambulans. Tujuan berikutnya dalam 
pengobatan adalah, reperfusi yang cepat, lengkap dan patensi yang baik pada 
pembuluh yang menyebabkan infark. Walaupun trombolitik dapat dipertimbangkan 
pada pasien tertentu dan bila Intervensi Koroner Perkutan (IKP) tidak tersedia, untuk 
sebagian besar pasien, IKP primer harus menjadi pilihan pertama. Setelah 
penanganan reperfusi, pasien harus diberi pengobatan antiplatelet, penyekat beta, 
obat penurun lipid dan pada pasien tertentu, penyekat Enzim Konversi Angiotensin 
(EKA). Rehabilitasi jantung sebaiknya dianjurkan kepada seluruh pasien dengan 
memperhatikan perubahan pola hidup, termasuk berhenti merokok.
Dalam bab S, dibahas lebih mendetail tentang Penyekat Glikoprotein (PG) IIb/IIIa, 
penggunaan tirofiban pada pasien dengan infark miokard. Tirofiban merupakan 
molekul kecil PG IIb/IIIa. Bila pemberian dihentikan, kerja tirofiban kembali lebih 
cepat dibandingkan abciximab, yaitu jenis PG IIb/IIIa lainnya. Dosis tirofiban 
beragam dari dosis kecil (bolus 0,4 Mg/kg bb diberikan selama S menit diikuti dengan 
pemberian melalui infus 0,10 Mg/kg bb/menit), dosis sedang (bolus 10 Mg/kg bb 
diberikan selama S menit diikuti dengan pemberian melalui infus 0,15 Mg/kg
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bb/menit) dan dosis tinggi (bolus 25 Mg/kg bb diberikan selama S menit diikuti dengan 
pemberian melalui infus 0,15 Mg/kg bb/menit),
Pemberian dosis tinggi, dapat memberi manfaat pada pasien dengan STEMI yang 
menjalani IKP primer. Tidak ada indikasi pemberian tirofiban pada pasien yang 
sudah ditangani dengan pemberian trombolisis. Pasien Non ST Elevation Myocard 
Infarction (NSTEMI) yang membutuhkan IKP memperoleh manfaat dari tirofiban ini, 
terutama bila pasien menderita iskemik yang terus-menerus dan/atau mengalami 
perubahan dinamik EKG. Seperti yang dijelaskan bahwa dengan penggunaan 
tirofiban dapat memberi komplikasi perdarahan yang serius dan mempunyai risiko 
rendah untuk terjadinya trombositopenia.
Dalam bab 4, dikaji manfaat potensial penggunaan stent pada IKP primer. Walaupun 
pada penelitian sebelumnya pemasangan stent pada pasien yang menjalani IKP 
primer berhubungan dengan penurunan risiko infark berulang dan revaskularisasi 
pembuluh target, namun tidak begitu jelas apakah pemasangan stent dapat juga 
menurunkan angka kematian bila dibandingkan dengan angioplasti balon. Untuk 
menilai adanya hubungan potensial antara kematian dan pemasangan stent pada 
IKP primer dalam praktik sehari-hari, kami menggunakan analisa registri prospektif 
dari Zwolle, Belanda. IKP primer dilakukan pada 4299 pasien dimana 2571 pasien 
(60%) ditangani dengan pemasangan stent (metal polos). Tidak ada perbedaan pada 
usia, jenis kelamin, lokasi infark atau diabetes diantara kedua kelompok, tetapi 
kelompok pasien yang menggunakan balon mempunyai riwayat infark miokard 
sebelumnya lebih sering dan penyakit pembuluh darah yang multipel dan 
mempunyai waktu yang lebih lama dari mulai timbulnya gejala sampai dengan 
masuk rumah sakit. Hasil akhir dari kombinasi dari kematian dan infark berulang 
setelah S0 hari adalah 7,2% pada kelompok balon dibanding 5,6% pada kelompok 
stent (p=0,0S). Setelah satu tahun pengamatan, kematian pada kelompok balon 
sebanyak 7,9% dibanding 5,8% dalam kelompok stent (p=0,007). Setelah 
penyesuaian perbedaan umur, jenis kelamin, infark miokard sebelumnya, 
keterlambatan pasien dan penyakit pembuluh koroner multipel, penggunaan stent 
tetap menunjukkan penurunan risiko kematian 1 tahun, dengan RO 0,77, IK 95% 
0,61-0,98. Penelitian ini menyimpulkan bahwa penggunaan stent pada praktik sehari- 
hari berhubungan dengan penurunan kematian.
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Dalam bab 5, dibandingkan dua jenis stent selaput obat pada pasien yang menjalani 
IKP primer. Dibanding dengan stent metal polos, baik stent selaput Sirolimus (SSS) 
dan stent selaput paclitaxel (SSP) menunjukan hasil akhir perbaikan angiografi dan 
klinis setelah prosedur IKP elektif dan pasien dengan STEMI. Tujuan penelitian ini 
yaitu membandingkan SSS terhadap SSP pada pasien dengan STEMI. Pasien 
dengan STEMI dilakukan randomisasi 1:1 menerima SSS (n=196) atau SSP 
(n=201). Titik akhir primer adalah kehilangan lumen secara lambat (KLL) pada bulan 
ke 9 dengan pemantauan angiografi koroner kwantitatif. Titik akhir sekunder adalah 
dampak kejadian utama klinis jantung yang merugikan (KUKJM) (kematian, infark 
ulangan, revaskularisasi pembuluh target) pada bulan pertama (1), sembilan (9) dan 
dua belas (12). Penelitian acak dilakukan kepada S97 pasien dengan STEMI.
Kedua kelompok mempunyai klinis dasar dan karakteristik angiografik yang 
sebanding. Angka kematian serendah 1,5% setelah S0 hari, 2,S% setelah 9 bulan 
dan S,1% setelah satu tahun. Tidak ada perbedaan hasil klinis pada setiap waktu 
pengamatan antara kedua kelompok yang ditangani. Pengamatan angiografi 
dilakukan pada 272 pasien dari S97 (69%). Rerata kehilangan lambat di dalam stent 
adalah 0,01 (0,42) mm dalam kelompok sirolimus dibanding 0,21 (0,50) mm 
dikelompok paclitaxel (perbedaan -0,20 mm, P=0,001). Disimpulkan bahwa pada 
pasien STEMI dengan IKP primer, SSS mengakibatkan kehilangan lambat yang lebih 
sedikit bila dibandingkan dengan PSS. Namun demikian, manfaat ini tidak dapat 
diterjemahkan adanya penurunan yang bermakna KUKJM dalam 1 tahun 
pengamatan.
Dalam bab 6, disajikan penelitian meta-analisa dari seluruh penelitian yang 
membandingkan stent selaput Rapamycin (SSR) dengan stent selaput Paclitaxel 
(SSP) pada pasien yang menjalani intervensi koroner perkutan. Oleh karena banyak 
penelitian individu yang kecil, maka tidak jelas apakah ada perbedaan antara SSR 
dan SSP untuk hasil akhir klinis. Pencarian secara sistematis dilakukan pada 
penelitian randomisasi terkontrol (PRT) yang membandingkan SSR dengan SSP di 
MEDLINE dan Database Cochrane secara sistematis. Informasi mengenai desain, 
kriteria eksklusi dan inklusi, jumlah pasien, dan hasil klinis dirangkum oleh 2 peneliti. 
Perbedaan pendapat diselesaikan secara konsensus. Hasil akhir primer adalah 
intervensi ulangan, revaskularisasi lesi target (RLT) dan revaskularisasi pembuluh 
target (RPT). Penyempitan berulang pada stent, infark miokard (IM) dan semua
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penyebab kematian merupakan titik akhir sekunder. Dua puluh satu PRT yang 
membandingkan SSR dengan SSP berjumlah 10.147 pasien dimasukan dalam 
meta-analisis ini. Indikasi angioplasti baik sindrom koroner akut atau angina stabil. 
Rerata periode pengamatan berkisar antara 6 - 24 bulan. Laju RLT 4,9% banding 
7,0%, p=0,0009 dan laju RPT 5,1% banding 8,S%; p<0,001 untuk SSR banding SSP 
secara respektif. Kejadian penyempitan kembali pada stent S,9% untuk SSR 
dibanding 5,S% untuk SSP; p=0,004. Laju IM dan semua penyebab kematian 
sebanding. Disimpulkan bahwa dibanding SSP, SSR menunjukkan risiko yang lebih 
rendah untuk intervensi ulangan dan stenosis berulang. Risiko IM dan seluruh 
penyebab kematian sama antara kedua stent.
Keamanan penggunaan rutin stent baru selaput antibodi sel progenitor endotelial 
pada pasien dengan IKP primer dikaji dalam Bab 7. Walaupun stent penangkap sel 
progenitor endothelial (SPE) mungkin aman dan secara potensial dapat mencegah 
trombosis dan stenosis berulang pada stent, data yang ada dalam penggunaanya 
pada IKP primer sangat terbatas. Data pasien konsekutif dengan STEMI yang 
ditangani dengan stent selaput-antibodi sel progenitor endotelial (Genous Bio­
Engineered R stent ) dihimpun dalam registri prospektif. Pemantauan klinis 
dilakukan pada hari ke S0 dan 1 tahun. Kejadian utama klinis jantung yang 
merugikan (KUKJM) didefinisikan sebagai kombinasi dari titik akhir kematian, IM 
ulangan, trombosis stent atau revaskularisasi tambahan, baik dengan IKP atau 
CABG. Dari Januari- September 2008, sejumlah 4S0 pasien STEMI konsekutif 
dimasukkan dalam registri. Dari semua pasien ini: 9% menderita diabetes dan S5% 
dengan infark anterior. Pada angiografi, 55% pasien mempunyai aliran TIMI 0, 
sebelum IKP. Lebih dari 1 stent diperlukan pada 20,2% pasien. Aliran TIMI S 
tercapai sebesar 94% pasien. Trombosis stent akut terjadi pada 1,2%. Ditemukan 
rendahnya insiden kejadian setelah 1 tahun pengamatan dengan angka kematian 
seluruhnya S,7% dan insiden trombosis stent yang lambat sebesar 0,8%. Prediktor 
KUKJM sampai dengan 1 tahun adalah kelompok usia yang lebih tua, tidak 
merokok, diameter stent yang lebih kecil, tidak didapatkan TIMI S setelah IKP dan 
penggunaan pompa balon intra aorta.
Disimpulkan bahwa penggunaan stent Genous yang berlapis sel antibodi progenitor 
endotelial ini aman dan berhubungan dengan laju kejadian yang rendah. 
Pengamatan lebih lama diperlukan untuk konfirmasi manfaat jangka panjang.
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Dalam bab 8, dijelaskan tentang 100 pasien yang ditangani dengan IKP primer di 
Klinik Kardiovaskular Hospital Cinere. IKP primer mungkin sangat efektif, tetapi 
sebagian besar penelitian dilakukan pada pusat yang berpengalaman di dunia barat. 
Pengalaman, logistik dan karakteristik pasien berbeda pada belahan dunia lain, 
terutama pada pusat jantung yang baru berdiri. Data dari seluruh 100 pasien 
konsekutif yang ditangani dengan IKP primer di rumah sakit Cinere, Jakarta, 
Indonesia dihimpun secara prospektif dari suatu database selama bulan Juli 2006 
sampai dengan Desember 2008. Rerata umur adalah 57 Tahun (kisaran S7-82), 88% 
adalah pria. Rerata waktu antara onset sakit dada dan masuk rumah sakit adalah 
S69 menit. Rerata waktu antara masuk dan inflasi balon adalah 258 menit. Sebelum 
IKP, 50% pasien mempunyai aliran TIMI 0. Setelah IKP, 94% dari pasien mempunyai 
aliran TIMI 2/S. Tidak ada pasien yang meninggal di ruang kateterisasi. Tidak ada 
pasien yang membutuhkan rujukan untuk bedah pintas koroner darurat sebagai 
komplikasi dari IKP. Rerata fraksi ejeksi ventrikel kiri yang diukur dengan 
ekokardiografi setelah 1 hari adalah 48%. Disimpulkan bahwa IKP primer efektif 
dalam memperbaiki aliran TIMI, tanpa komplikasi. Keterlambatan waktu antara onset 
keluhan, saat masuk dan pengembangan balon cukup lama dan harus dilakukan 
seluruh usaha untuk memperbaiki masalah ini.
Dalam Bab 9, pasien konsekutif yang ditangani antara Januari - Oktober 2008 
dengan IKP primer di rumah sakit Cinere, Jakarta, Indonesia dibandingkan dengan 
waktu yang sama di Isala Klinieken, Zwolle, Belanda. Selama periode penelitian, 
sejumlah 596 pasien yang ditangani IKP primer, 568 pasien di Zwolle, dan 28 pasien 
di Cinere, Jakarta. Pasien di Indonesia lebih muda (54 tahun dibanding 6S tahun), 
lebih banyak menderita diabetes (S6% dibanding 12%) dan lipid yang tinggi dan 
sebagian besar merokok (68% dibanding S1%). Keterlambatan waktu antara onset 
keluhan dan masuk rumah sakit lebih lama di Indonesia. Pasien dari Indonesia lebih 
sering memiliki tanda gagal jantung saat masuk. Waktu antara masuk rumah sakit 
dan inflasi balon lebih lama di Indonesia. Pada pemerikasaan angiografi, pasien 
Indonesia lebih sering mempunyai penyakit pembuluh darah multipel. Tidak ada 
perbedaan persentase perbaikan aliran TIMI S dengan IPK primer antara kedua 
rumah sakit.
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Disimpulkan bahwa pasien dengan STEMI di Indonesia mempunyai profil risiko lebih 
tinggi dibandingkan di Belanda, menurut prevalensi faktor risiko koroner, tanda gagal 
jantung, penyakit pembuluh darah multipel dan keterlambatan pasien. Keterlambatan 
waktu antara masuk rumah sakit dan pengembangan balon lebih lama di Indonesia, 
oleh karena masalah logistik dan finansial.
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being there when you needed me. Your understanding of daddy’s schedules of 
working and studying is highly appreciated. You are great children; you have become 
the source of motivation for daddy to be a better person. Papa sayang kalian.
Finally, I would like to express my sincere gratitude to my beloved parents. To my 
mother Aisah who raised her 6 children with care, love and endless pray for success 
in life and career. The encouragement you have given over the years and years to 
come has become gift to us, your children.
To my father Juwana, thank you for your guidance, support and endless pray, day 
and night over the years and I believe in the years to come. You have supported my 
decision to become a medical doctor on an early age, even though there were many 
obstacles. You believe that education is the best investment for the children. You 
have supported and guided all the children to obtain quality education and have 
made what we become today. The discipline, commitment and professionalism to 
work and caring of the family that you have exemplified and showed are my biggest 
motivation to conquer challenges and achieve success.
I cannot thank my parents enough with thousands words or luxury goods as I know 
that is not what they need. But to show my profound gratitude of having parents like 
them let me give today’s procession as a tribute to my parents and I can only pray 
that the Lord almighty will return their good deeds. I am blessed by the Lord to have 
you both as my parents.
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Chapter 15 
Curriculum vitae
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Personality
Name
Born, place/date
Religion
Status
Wife
Childeren
Yahya Berkahanto Juwana 
Blora, 1B Februari 19B9 
Islam 
Maried
Syukrini Bahri Padang, 10 April 19BB. 
Safira, Jakarta, I7 Agustus 1995 
Adam, Jakarta, 13 Januari 1998 
Juwana, Blora 10 September 19SB 
Siti Aisa , Malang 9 October 1938
Father
Mother
Working place
Klinik Kardiovaskular, Hospital Cinere, Jakarta, Indonesia 
Qualifications :
Graduated as General Practitioner, Medicine Faculty, University of YARSI, Jakarta, 
Indonesia.
Post Graduate study in Cardiology at Medicine Faculty, University of Indonesia/ 
National Cardiovascular Center "Harapan Kita” , Jakarta, Indonesia.
2004 - 2005 Interventional Cardiology Training, Leiden University Medical Centre, 
Leiden, Netherlands
Experiences :
1995 -1998 Head of the Public Health Community (Puskesmas) Kesumadadi, 
Lampung, Sumatera.
1998 Medical Doctor in Department of Emergency, Persahabatan Hospital, Jakarta.
2003 - Cardiologist, at Klinik Kardiovaskular RS. Hospital Cinere, Jakarta, Indonesia, 
head of Cath lab
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